Cumulative Index—1982, 1983, and 1984

Volumes 3, 4, and 5

Note: The volume year is in *italic* type. Page numbers of symposium and article titles are in **boldface** type.

SYMPOSIA

1982

January	ADULT RESPIRATORY DISTRESS SYNDROME
May	RECENT ADVANCES IN LUNG CANCER
September	INTERSTITIAL LUNG DISEASES

1983

January	IMMUNE FACTORS IN PULMONARY DISEASE
May	CARDIOVASCULAR-PULMONARY INTERACTION IN NORMAL AND DISEASED LUNGS
September	EMPHYSEMA

1984

March	EXERCISE: PHYSIOLOGY AND CLINICAL APPLICATIONS
June	CHEST RADIOLOGY
September	PULMONARY EMBOLISM AND HYPERTENSION
December	ASTHMA

Abdominal pressure, effect on left ventricular performance, *1983*: May, 163
Abscess, lung, CT evaluation of, *1984*: June, 277–279
  ultrasound evaluation of, *1984*: June, 286
  vs. bronchopleural fistula, on CT, *1984*: June, 277–279
ACTH, ectopic secretion of, in lung cancer, *1982*: May, 308–310, 312
  role in small cell carcinoma of lung, *1982*: May, 262–264
Acute respiratory failure, left ventricular function in, *1983*: May, 253
  oxygen transport in, *1983*: May, 105
  right ventricular function in, *1983*: May, 260
Adenocarcinoma, of lung, pathology of, *1982*: May, 276–282
Adrenal glands, metastases to, evaluation of, *1984*: June, 360
Adrenergic agonists, for asthma, *1984*: Dec., **659–668**
  complications of, *1984*: Dec., 706
  pharmacology of, *1984*: Dec., 659–660
Adult respiratory distress syndrome. See *Respiratory distress syndrome, adult.*
Aerobic capacity, *1983*: May, 101, 104; *1984*: Mar., 56
  determining, *1984*: Mar., 174, 175
  impairment of, causes of, *1984*: Mar., 176
  in occupational lung disease, *1984*: Mar., 160
  of kidney, *1983*: May, 104
Aerosols, as environmental hazards, assessment of, *1981*: Sept., 318–322
Air, extra-alveolar, radiographic findings in, *1984*: June, 253–255
Air embolism, with invasive hemodynamic monitoring, *1983*: May, 242
Air pollution, as risk factor in emphysema, *1983*: Sept., 356–357
  asthma and, *1984*: Dec., 560, 594
  lung cancer and, *1982*: May, 223
  role in airways obstruction, *1983*: Sept., 366
Airflow, reduced, in asthma, *1984*: Dec., 573–580
Airflow obstruction, cardiovascular effects of, *1984*: Dec., 624–626
  chronic, in emphysema, *1983*: Sept., 344–345
  epidemiology of, *1983*: Sept., 351
  in asthma, *1984*: Dec., 567
  in emphysema, *1983*: Sept., **413–420**

Airflow obstruction (*Continued*)
in marathon runners, *1984*: Mar., 67
in severe asthma, *1984*: Dec., 623–624
mistaken for asthma, *1984*: Dec., 696–697
pulmonary effects of, *1984*: Dec., 624
response on exercise testing, *1984*: Mar., 103, 105
reversibility of, in asthma, *1984*: Dec., 580
severity of emphysema and, *1983*: Sept., 333–334
Airway(s), collapsibility of, effects on cardiac output, *1983*: May, 115
edematous, in asthma, *1984*: Dec., 568–569
obstruction of, interstitial disease and, *1982*: Sept., 462
sarcoidosis and, *1982*: Sept., 549
Airway cooling, bronchospasm due to, *1984*: Mar., 112, 115
Airway pressure, heart-lung relationships and, *1983*: May, 108
Airway reactivity, nonspecific, exercise-induced asthma and, *1984*: Mar., 113–115
Allergic bronchopulmonary aspergillosis, immune factors in, *1983*: Jan., **15–22**
Allergy, asthma and, *1984*: Dec., 559–560
mechanisms of, *1984*: Dec., 599–600
diagnosis of, *1984*: Dec., 602–604
respiratory, induced by fungi, *1983*: Jan., **23–41**
Alpha-adrenergic antagonists, for asthma, *1984*: Dec., 690
Alpha-1-antitrypsin deficiency, as risk factor for emphysema, *1983*: Sept., 351
biochemistry of, *1983*: Sept., 359–360
panacinar emphysema and, *1983*: Sept., 330
physiologic role of, *1983*: Sept., 360
role in emphysema, *1983*: Sept., 359–375
therapy for, *1983*: Sept., 368–370
Alpha-1-protease inhibitor. See *Alpha-1-antitrypsin deficiency*.
Alpha-1-proteinase inhibitor deficiency. See *Alpha-1-antitrypsin deficiency*.
Alpha-2-macroglobulin, as elastase inhibitor, *1983*: Sept., 408
Altitude, chronic hypoxia of, *1983*: May, 297
Alveolar capillaries, structure of *1983*: May, 200–201
Alveolar pressure, effects on pulmonary vascular resistance, *1983*: May, 131
Alveolar ventilation, in infants and children, *1983*: May, 219
Alveolar walls, destruction of, in emphysema, *1983*: Sept., 338–339
effect of PEEP on, *1982*: Jan., 72–73
Alveolitis, *1982*: Sept., 492
extrinsic allergic, *1982*: Sept., **503–519**
of sarcoidosis, *1982*: Sept., 542, 544
treatment of, *1982*: Sept., 469
Aminophylline, for asthma, *1984*: Dec., 648
in COPD, *1984*: Mar., 134
to improve diaphragmatic contractility, *1983*: Sept., 430–431
Aminorex, pulmonary hypertension due to, *1983*: May, 208
Ampicillin, as cause of occupational asthma, *1983*: Jan., 49
Anaerobic capacity, *1984*: Mar., 56
Anaerobic metabolism, gas exchange changes in, *1984*: Mar., 84
Anaerobic threshold, *1983*: May, 105
in COPD, *1984*: Mar., 125
measurement in exercise testing, *1984*: Mar., **77–88**
protocol for, *1984*: Mar., 174, 175
oxygen uptake at, *1984*: Mar., 92
Anaerobic threshold hypothesis, *1984*: Mar., 77–88
Anaphylaxis, exercise-induced, *1984*: Mar., 116
Ancrod, in prevention of thromboembolic disease, *1984*: Sept., 484
Anemia, hypoxia with, *1983*: May, 139–140
oxygen transport in, *1983*: May, 105
Anergy, in pulmonary sarcoidosis, *1982*: Sept., 549
Anesthesia, general, for severe asthma, *1984*: Dec., 632
Aneurysm, aortic, CT evaluation of, *1984*: June, 257, 294
Angiitis, benign lymphocytic, *1982*: Sept., 612
Angiography, bronchial, in chronic unresolved pulmonary embolism, *1984*: Sept., 522–523
contrast, in cor pulmonale, *1983*: May, 275
digital subtraction, in diagnosis of pulmonary embolism, *1984*: Sept., 386, 472–476
in evaluating for bullectomy, *1983*: Sept., 458
pulmonary, in diagnosis of pulmonary embolism, *1984*: Sept., 386, **465–477**. See also *Pulmonary angiography*.
Anticoagulant therapy, oral, for prevention of venous thromboembolic disease, *1984*: Sept., 398
Angiotensin conversion, in experimental emphysema, *1983*: Sept., 397
Angiotensin-converting enzyme, pulmonary sarcoidosis and, *1982*: Sept., 550
"Anterior pericardial stripe," on radiography, *1984*: June, 239
Antibiotics, for complications of medical management of emphysema, *1983*: Sept., 471–472
Anticholinergic agents, for asthma, *1984*: Dec., 685–687
Antidiuretic hormone, effect of PEEP on, *1983*: May, 180
Antielastase therapy, for emphysema, *1983*: Sept., 335
Antigenic stimulation, of parenchymal cells, *1981*: Sept., 363
Antigens, as cause of asthma, *1984*: Dec., 600–602
Antihistamines, for asthma, *1984*: Dec., 690–691
Antimicrobial agents, for severe asthma, *1984*: Dec., 631–632
Antimuscarinic agents, for severe asthma, *1984*: Dec., 631
Antinuclear antibody, in asbestosis, *1983*: Jan., 5
Antinuclear antibody assays, for diagnosis of occupational lung disease, *1983*: Jan., 90–91
Antithrombin III deficiency, congenital, chronic unresolved pulmonary embolism due to, *1984*: Sept., 512
Anxiety, mistaken for asthma, *1984*: Sept., 695–696
Aorta, aneurysm of, CT evaluation of, *1984*: June, 257, 294
dissection of, CT evaluation of, *1984*: June, 257–258, 294–296
thoracic, DSA of, *1984*: June, 318
trauma to, CT evaluation of, *1984*: June, 296
Aortic disease, acute, CT evaluation of, *1984*: June, 257–258
Aortic insufficiency, exercise testing in, *1984*: Mar., 183
Aortic pressure, transmural, IPPV and, *1983*: May, 179
Aortic valve disease, pulmonary embolism after, right ventricular response to, *1984*: Sept., 431–432
APUD cells, in etiology of small cell lung cancer, *1982*: May, 264, 267, 389
Arachidonic acid, cyclo-oxygenase products of, *1982*: Jan., 13–17
lipoxygenase products of, *1982*: Jan., 17–18
metabolism of, *1982*: Jan., 11–13
ARDS. See *Respiratory distress syndrome, adult*.
Arrhythmias, cardiac, during insertion of catheter, *1982*: Jan., 166
in adult respiratory distress syndrome, *1982*: Jan., 149
ventricular, with insertion of pulmonary artery line, *1983*: May, 242

Arsenic, lung cancer and, *1982*: May, 223
Arterial blood gases. See *Blood gases, arterial.*
Arterial blood pressure, decreased cardiac output and, *1983*: May, 164
  PEEP and, *1983*: May, 180
Arteriovenous malformation, venous return curve with, *1983*: May, 116
Arteriovenous oxygen difference, *1983*: May, 104
Arteriovenous shunt(s), *1983*: May, 144
Arteritis, familial granulomatous, *1982*: Sept., 639
Arthritis, rheumatoid, alpha-1-antitrypsin deficiency and, *1983*: Sept., 368
Asbestos, lung cancer and, *1982*: May, 223–224
Asbestosis, exercise testing in, *1984*: Mar., 158
  immune factors in, *1983*: Jan., 3–6
Aspergillosis, allergic bronchopulmonary, *1982*: Sept., 509
  complicating management of asthma, *1984*: Dec., 702
  immune factors in, *1983*: Jan., 15–22
Aspergillus fumigatus, *1982*: Sept., 509
Aspiration, chronic, and esophageal reflux, in difficult asthma, *1984*: Dec., 704
Aspiration pneumonia, as cause of adult respiratory distress syndrome, *1982*: Jan., 197
Aspiration pneumonitis, *1982*: Jan., 25–34
  radiographic findings in, *1984*: June, 249–250
Aspirin, in inducing asthma, 1984: Dec., 592
  in treatment of venous thromboembolic disease, *1984*: Sept., 484
Asthma, adult-onset, as difficult asthma, *1984*: Dec., 696
  allergic bronchopulmonary aspergillosis and, *1983*: Jan., **15–22**
  alpha-1-antitrypsin deficiency and, *1983*: Sept., 368
  bronchial. See *Bronchial Asthma.*
  changes in pleural pressure with, *1983*: May, 167
  corticosteroids for, *1984*: Dec., **669–683**
  death from, *1984*: Dec., 632–633
  difficult, *1984*: Dec., **695–713**
  epidemiology of, *1984*: Dec., **557–565**
  episode of, assessing severity of, *1984*: Dec., 626–628
  exercise-induced, *1984*: Dec., 581–582, 638
  functional aspects of, *1984*: Dec., **573–587**
  immunologic aspects of, *1984*: Dec., **599–606**
  in children, *1984*: Dec., **635–643**
  left ventricular function in, *1983*: May, 168
  natural history of, *1984*: Dec., **557–565**
  occupational, *1984*: Dec., 560, 595, **619–622**
    immune factors in, *1983*: Jan., **43–53**
  pathogenesis of, *1984*: Dec., 671–672
  pathology of, *1984*: Dec., **567–571**
  pathophysiology of, *1984*: Dec., **589–597**
  pulmonary gas exchange in, *1983*: May, 155
  severe, pathophysiology and management of, *1984*: Dec., **623–634**
    acute, management of, *1984*: Dec., 702
  symposium on, *1984*: Dec., **555–713**
  theophylline for, *1984*: Dec., **645–658**
  ventilatory control in, *1984*: Dec., **607–617**
Atelectasis, radiographic findings in, *1984*: June, 247–249
Atrial pressure, average, calculation of, *1983*: May, 124–125
  overall, *1983*: May, 118
  right, cardiac output and, *1983*: May, 115–117
  venous return and *1983*: May, 119
Atrial septal defects, circulatory pathology in, *1983*: May, 221–225
Autonomic nervous system, in asthma, *1984*: Dec., 590–592, 672
Auxometry, in staging lung cancer, *1982*: May, 296
Avian proteins, pulmonary hypersensitivity to, *1982*: Sept., 508
Azathioprine, interstitial lung disease and, *1982*: Sept., 523

Bacillus Calmette-Guerin, for immunotherapy of lung cancer, *1982*: May, 428–433
Bacteremia, gram-negative, corticosteroids for, *1982*: Jan., 124–129
Bacteria, colonization of, bronchopulmonary infection and, *1982*: Jan., **133–142**
Bacterial pneumonia, in immunocompromised host, *1981*: Jan., 20
Barotrauma, pulmonary, as complication in adult respiratory distress syndrome, *1982*: Jan., 144
  in ventilated patients, *1984*: June, 253, 262
  PEEP for, *1982*: Jan., 74–75
Base excess, oxygen consumption and, *1984*: Mar., 190
Behçet's syndrome, pulmonary involvement in, *1982*: Sept., 615
Benign lymphocytic angiitis, *1982*: Sept., 631
Beryllium, lung cancer and, *1982*: May, 226
Beta-adrenergic agonists, aerosol therapy with, *1984*: Dec., 664–665
  effect on respiratory regulation, *1984*: Dec., 614–615
  for severe asthma, *1984*: Dec., 630–631
  in cor pulmonale, *1983*: May, 287
  in COPD, *1984*: Mar., 135
  in management of emphysema, *1983*: Sept., 469–471
  intravenous administration of, *1984*: Dec., 666–667
  oral therapy with, *1984*: Dec., 665
  subcutaneous administration of, *1984*: Dec., 665–666
  with theophylline, 1984: Dec., 654
Bicarbonate, changes during exercise, *1984*: Mar., 80
Bidirectional shunts, in infants and children, *1983*: May, 227
Biopsy, aspiration, percutaneous, *1982*: Sept., 494
  open lung, *1981*: Jan., 13–15; *1982*: Sept., 485–490, 495
    anesthesia for, *1982*: Sept., 486
    surgical procedure, *1982*: Sept., 486, 687
  scalene node, *1982*: Sept., 487
Bleomycin, fibrosis and, *1982*: Sept., 523–525
Blood, viscosity of, venous return curve and, *1983*: May, 116
Blood flow, control of, vasculature in, *1983*: May, 119
  during cardiopulmonary resuscitation, *1983*: May, 190–197
  peripheral, autoregulation of, *1983*: May, 145–146
  pulmonary, *1983*: May, 102–103
    alterations in, *1983*: May, 152
Blood gas(es), arterial, *1983*: May, 150
    abnormalities in, pulmonary embolism and, *1984*: Sept., 416
    during exercise testing, *1984*: Mar., 93
    in COPD, *1984*: Mar., 126
  in emphysema, 1984: Mar., 127
    in idiopathic pulmonary fibrosis, *1984*: Mar., 149
Blood group, risk of pulmonary embolism and, *1984*: Sept., 395
Blood lactate level, changes in exercise, *1984*: Mar., 81–83
Blood pressure, arterial, decreased cardiac output and, *1983*: May, 164
    PEEP and, *1983*: May, 180
Blood vessels, pressure-flow curves of, *1983*: May, 127–131

Blood volume, circulating during exercise, *1984*: Mar., 17
diuretic-induced decrease in, hemodynamic effects of, *1983*: May, 122
maximum transferable, *1983*: May, 193
pulmonary, *1983*: May, 103
"Blue bloater," definition of, *1983*: Sept., 333
Body fuels, effects of physical training on, *1984*: Mar., 8–9
utilization and production of, *1984*: Mar., 3–6
Body heat, transfer of, *1984*: Mar., 13–15
Body temperature, regulation of, exercise and, *1984*: Mar., 13–20
physiology of, *1984*: Mar., 15–17
Bohr pulmonary dead space, *1984*: Sept., 418
Borg scale, *1984*: Mar., 100
Bradycardia, effect on cardiac output, *1983*: May, 119
Bradykinin, role in adult respiratory distress syndrome, *1982*: Jan., 21
Bradykinin clearance. in experimental emphysema, *1983*: Sept, 397
Breast-feeding, in reducing atopic disease, *1984*: Dec., 561
Breathing, during exercise, *1984*: Mar., 36, 40
in COPD, *1984*: Mar., 124
Breathlessness, in COPD, *1984*: Mar., 128–129
Bronchi, CT anatomy of, *1984*: June, 266–267
mucoid impaction of, allergic bronchopulmonary aspergillosis and, *1983*: Jan., 17
Bronchial angiography, in chronic unresolved pulmonary embolism, *1984*: Sept., 522–523
Bronchial asthma, exercise-induced, *1984*: Mar., 109–119
challenge procedures for, *1984*: Mar., 115
heat loss in, *1984*: Mar., 111–113
hyperventilation in, *1984*: Mar., 111–113
nonspecific airways reactivity and, *1984*: Mar., 113–115
therapeutic considerations in, *1984*: Mar., 117
physiologic responses to exercise in, *1984*: Mar., 109–111
Bronchial lavage, for severe asthma, *1984*: Dec., 632
Bronchial mucus inhibitor, as elastase inhibitor, *1983*: Sept., 408
Bronchial provocation testing, in asthmatics, *1984*: Dec., 581
Bronchiectasis, central, in allergic bronchopulmonary aspergillosis, *1983*: Jan., 18
in difficult asthma, *1984*: Dec., 698
Bronchiolitis, in children, *1984*: Dec., 636–637
Bronchitis, chronic, cor pulmonale in, *1983*: May, 203
exercise arterial blood gases in, *1984*: Mar., 127
in difficult asthma, *1984*: Dec., 697–698
nosologic differences, *1983*: Sept., 332
pulmonary artery pressure and pulmonary vascular resistance in, *1983*: May, 270
ventilation in, *1984*: Mar., 128
with emphysema, *1983*: Sept., 331
left ventricular function in, *1983*: May, 283–284
oxygen therapy in, *1983*: May, 300–303
pulmonary hypertension in, *1983*: May, 298–300
Bronchoalveolar lavage, *1982*: Sept., 466, 468, 469, 495, 496
in inflammatory lung disease, *1983*: Jan., **71–84**
in interstitial disease, *1982*: Sept., 466, 468, 495, 496
staging of pulmonary sarcoidosis, *1982*: Sept., 553–555
Bronchoconstriction, after exercise, *1984*: Dec., 581–582
in asthma, *1984*: Dec., 570
Bronchodilation, with theophylline, *1984*: Dec., 646–647
Bronchodilator aerosols, for asthma, *1984*: Dec., **659–668**
Bronchodilator agents, for severe asthma, *1984*: Dec., 630–631
Bronchogenic carcinoma, non–small cell, staging of, *1984*: June, 350–361
imaging of extrathoracic metastases to aid in, *1984*: June, 359–361
imaging of intrathoracic extent of tumor to aid in, *1984*: June, 354–359
occult, CT identification of, *1984*: June, 275
Bronchopleural fistula, CT evaluation of, *1984*: June, 277–279
Bronchoscopy, fiberoptic, for hilar masses, *1984*: June, 374
for localizing lung cancer, *1982*: May, 322–325
for lung lesions, *1984*: June, 372–374
for mediastinal masses, *1984*: June, 374–376
for severe asthma, *1984*: Dec., 632
with transbronchial biopsy, for diagnosing diffuse infiltrative pulmonary disease, *1983*: Jan., 74–75
Bronchospasm, due to airway cooling, *1984*: Mar., 112, 115
nocturnal, theophylline for, *1984*: Dec., 655
postoperative, *1984*: Dec., 701
Bulla(ae), with emphysema, surgical management of, *1983*: Sept., 447–461
Bullous emphysema, surgical management of, *1983*: Sept., 447–461
Burkard spore, sampler, *1983*: Jan., 31
Burns, surface, as cause of adult respiratory distress syndrome, *1982*: Jan., 205
Busulfan, interstitial lung disease and, *1982*: Sept., 525, 526
Byssinosis, *1982*: Sept., 507, 508
classification of, *1983*: Jan., 64
immune factors in, *1983*: Jan., **63–70**

Cadmium, administration of, in pathogenesis of emphysema, *1983*: Sept., 399
Calcitonin, excessive levels of, in lung cancer, *1982*: May, 312
Calcium, elevated levels of, in lung cancer, *1982*: May, 312–313
Calcium channel blocking agents, for asthma, *1984*: Dec., 688–689
Cancer, of the lung. See *Lung cancer*.
Carbon dioxide gradient, arterial-alveolar, clinical value of, *1984*: Sept., 418
Carbon dioxide transport, *1983*: May, 104–105
Carbohydrate loading, in endurance exercise, *1984*: Mar., 73
Carcinoids, of lung, pathology of, *1982*: May, 274
Carcinoma, as risk factor for pulmonary embolism, *1984*: Sept., 393–394, 514
bronchogenic. See *Bronchogenic carcinoma*.
esophageal, CT staging of, *1984*: June, 298–299
of lung. See *Lung carcinoma*.
giant cell, pathology of, *1982*: May, 282–283
large cell, pathology of, *1982*: May, 280–282
small cell. See *Small cell lung cancer*.
squamous cell, pathology of, *1982*: May, 257–262
Cardiac dyspnea, response on exercise testing, *1984*: Mar., 104
Cardiac function, abdominal pressure and, *1983*: May, 163
effect on pulmonary gas exchange, *1983*: May, **149–159**
lung function and, *1983*: May, 108–109
PEEP and, *1983*: May, 181
pressure ventilation and, *1983*: May, **161–187**
vascular function and, *1983*: May, 119–124
Cardiac glycosides, in cor pulmonale, *1983*: May, 122

Cardiac hypertrophy, endurance exercise and, *1984*: Mar., 68
Cardiac index, after pulmonary embolism, *1984*: Sept., 424–425, 427, 433–434
  mean pulmonary artery pressure and, pulmonary embolism and, *1984*: Sept., 428
  systemic arterial hypoxemia and, *1984*: Sept., 424
cardiac output, *1983*: May, 119
  collapsibility of airways and, *1983*: May, 115
  collapsibility of great veins and, *1983*: May, 113–115
  decreased, arterial blood pressure and, *1983*: May, 164
  effects of PEEP on, *1982*: Jan., 177–178
  effects on pulmonary gas exchange, *1983*: May, 150–153
  in endurance exercise, *1984*: Mar., 68
  in infants and children, *1983*: May, 220
  maximal, *1984*: Mar., 53
  measuring, thermodilution technique for, *1983*: May, 240
    with balloon-flotation catheter, *1982*: Jan., 159–160
  normal distribution of, *1983*: May, 102
  PEEP and, *1982*: Jan., 163–165; *1983*: May, 122–124
    decreased, *1982*: Jan., 73–76
    increased, *1982*: Jan., 76
  pleural pressure and, *1983*: May, 190
  regulation of, *1983*: May, 119–120
    vasculature in, *1983*: May, **111–126**
  right atrial pressure and, *1983*: May, 115
  venous return curve and, *1983*: May, 115–117
Cardiac pressure, transmural, *1983*: May, 168
Cardiac surgery, CT after, *1984*: June, 260
Cardioacceleration, on exercise testing, *1984*: Mar., 194–195
Cardiopulmonary disease, acute, diagnostic imaging in, *1984*: June, **247–264**
  exercise testing in, *1984*: Mar., **173–187**
  pulmonary embolism after, hemodynamic changes after, *1984*: Sept., 426–429
Cardiopulmonary function, in children, *1983*: May, 219–221
Cardiopulmonary gas transport unit, *1983*: May, 103
  functional aspects of, *1983*: May, **101–110**
Cardiopulmonary interaction, *1983*: May, 101, 108–109, **149–159**
  in congenital heart disease, *1983*: May, **219–232**
  symposium on, *1983*: May, **101–319**
Cardiopulmonary resuscitation, *1983*: May, **189–198**
  blood flow to vital organs in, *1983*: May, 196
  physiology of, *1983*: May, 104, 190–197
  theoretical models of, *1983*: May, 192–195
  thoracic mechanics and, *1983*: May, 191–192
Cardiovascular disease, acute, diagnostic imaging in, *1984*: June, **255–258**
Cardiovascular function, effects on gas exchange, *1983*: May, **149–159**
  in cor pulmonale, *1983*: May, **269–295**
Cardiovascular-pulmonary interaction, symposium on, *1983*: May, **101–319**
Cardiovascular shunts. See *Left-to-right shunts* and *Right-to-left shunts*.
Cardiovascular system, mean systemic pressure of, *1983*: May, 112, 114, 117
  response to endurance exercise, *1984*: Mar., 67–68
Cartilage, bronchial, atrophy of, in severe emphysema, *1983*: Sept., 333
Castor bean dust, as cause of occupational asthma, *1983*: Jan., 46–47
Catecholamines, metabolic effects of, *1983*: May, 143
  with corticosteroid therapy, *1984*: Dec., 674–675
Cathepsin G, in pathogenesis of emphysema, *1983*: Sept., 405–406
Catheter(s), flotation, insertion of, *1982*: Jan., 157
  intravenous, positioning of, radiography for, *1984*: June, 263
  Swan-Ganz, complications of adult respiratory distress syndrome with use of, *1982*: Jan., 145
    positioning of, radiography for, *1984*: June, 263
Catheterization, pulmonary artery, complications of, *1982*: Jan., 165–166
Centriacinar emphysema, in epidemiologic studies, *1983*: Sept., 353
Centrilobular emphysema, in epidemiologic studies, *1983*: Sept., 353
  pathologic classification of, *1983*: Sept., 330
Cerebral blood flow, during CPR, *1983*: May, 196
Charcot-Leyden crystals, in sputum of asthmatics, *1984*: Dec., 569
Chemical mediators, in allergic asthma, *1984*: Dec., 672–674
Chemotherapy, as prognostic factor in lung cancer, *1982*: May, 236
  for non–small cell lung carcinoma, *1982*: May, **399–414**
  for small cell cancer of lung, *1982*: May, 391–392
Chemotherapy-induced interstitial lung disease, *1982*: Sept., 521–529
Chest, diagnostic ultrasound of, *1984*: June, **281–290**
  DSA of, *1984*: June, 313–328
  mechanics of, cardiopulmonary resuscitation and, *1983*: May, 191–192
  NMR studies of, *1984*: June, **307–312**
  oxygen requirements of, *1983*: May, 101
  pressure events in, *1983*: May, 103
  pump function of, *1983*: May, 109
  radiographs of, anatomic considerations for, *1984*: June, **213–246**
    appearance of lung cancer on, *1982*: May, 232
    for early detection of lung cancer, *1982*: May, 230–231, 248–250, 321, 337
    for staging bronchogenic carcinoma, *1982*: May, 294, 338–339
  radiology of, symposium on, *1984*: June, **213–337**
  respiratory motion of, *1983*: May, 108
Chest wall, CT evaluation of, *1984*: June, 279
  in experimental emphysema, *1983*: Sept., 395
  mechanics of, in COPD, *1984*: Mar., 122
Children, alveolar ventilation in, *1983*: May, 219
  cardiac output in, *1983*: May, 220
  cardiopulmonary function in, *1983*: May, 219–221
  functional residual capacity in, *1983*: May, 220
  left-to-right shunts in, *1983*: May, 221–227
  oxygen transport in, *1983*: May, 220
  reactive airway disorders in, *1984*: Dec., **635–643**
  right-to-left shunts in, *1983*: May, 227–230
Chlorambucil, interstitial lung disease and, *1982*: Sept., 526
Chloramine T, in development of emphysema, *1982*: Sept., 398
Chloromethyl ethers, lung cancer and, *1982*: May, 224
Chloromethyl ketone compounds, for experimental emphysema, *1983*: Sept., 397
Chloroprene, lung cancer and, *1982*: May, 226
Cholinergic nervous system, in asthma, *1984*: Dec., 591–592
Chromium, lung cancer and, *1982*: May, 224
Chronic diffuse infiltrative lung disease. See *Lung disease, chronic diffuse infiltrative*.
Chronic obstructive lung disease, abnormal gas exchange in, *1983*: May, 155
  acute respiratory failure with, *1983*: May, 245
  changes in pleural pressure with, *1983*: May, 167

Chronic obstructive pulmonary disease (COPD), aminophylline in, *1984*: Mar., 134
anaerobic threshold in, *1983*: Mar., 125
beta$_2$ agonists in, *1984*: Mar., 135
breathing work in, *1984*: Mar., 124
breathlessness in, *1984*: Mar., 128–129
chest wall mechanics in, *1984*: Mar., 122
compliance in, *1984*: Mar., 121
congestive heart failure and, *1984*: June, 257
cor pulmonale and, *1983*: May, **269–295**; *1984*: Mar., 129–131
definition of, *1983*: Sept., 334
diaphragm in, *1984*: Mar., 124
digoxin in, *1984*: Mar., 136
diuretics in, *1983*: May, 286
dyspnea in, *1984*: Mar., 128
exercise arterial blood gases in, *1984*: Mar., 126
exercise impairment in, *1984*: Mar., **121–143**
exercise performance in, nutritional status and, *1984*: Mar., 131
therapeutic alteration of, *1984*: Mar., 133
training for, *1984*: Mar., 137
exercise testing in, *1984*: Mar., 132–133, 185–187
familial aggregation and, *1983*: Sept., **377–387**
flow-volume curves in, *1984*: Mar., 122
flow-volume rate during, *1984*: Mar., 37
gas exchange in, *1984*: Mar., 125–128
hereditary factors in, *1983*: Sept., **377–387**
left ventricular ejection fraction in, *1984*: Mar., 130
left ventricular function in, *1983*: May, 168, 174–176, 283–285.
lung volumes in, *1984*: Mar., 121
maximal oxygen uptake in, *1984*: Mar., 125
maximum ventilatory capacity in, *1984*: Mar., 122
oxygen pulse in, *1984*: Mar., 125
oxygen therapy in, *1983*: May, 285; *1984*: Mar., 133
pulmonary artery pressure in, *1983*: May, 269
pulmonary mechanics in, *1984*: Mar., 121–124
pulmonary vascular resistance in, *1983*: May, 269
respiratory exchange ratio in, *1984*: Mar., 125
respiratory muscles in, *1984*: Mar., 124–125
response to exercise in, *1984*: Mar., 185–187
right ventricular dysfunction in, *1984*: Mar., 131
right ventricular ejection fraction in, *1984*: Mar., 130
right ventricular overload with, *1983*: May, 120
terbutaline in, *1984*: Mar., 135
theophylline in, *1984*: Mar., 134
transpulmonary pressure in, *1984*: Mar., 121
vasodilators in, *1984*: Mar., 135
ventilatory pump in, *1984*: Mar., 44
Chronometry, in staging lung cancer, *1982*: May, 296
CIE. See *Crossed immunoelectrophoresis*.
Circulation, control of blood flow in, *1983*: May, 119
homeostasis of, *1983*: May, 103, 105
models of, *1983*: May, 113, 192
peripheral, maximal oxygen uptake and, *1984*: Mar., 54
types of cells in, *1983*: May, 200
pulmonary, *1983*: May, 102–103
control of, *1983*: May, 202
pulmonary arterial, at birth, *1983*: May, 201–202
normal structure of, *1983*: May, 199–201
systemic arterial, intrathoracic and extrathoracic components of, *1983*: May, 103–104
Circulatory failure, exercise testing for, *1984*: Mar., 175–179
Circulatory system, models of, *1983*: May, 113–118
Clq binding assay, for diagnosis of occupational lung disease, *1983*: Jan., 91
Coal workers' pneumoconiosis, immune factors in, *1983*: Jan., 9–11
Coffee beans, green, as cause of occupational asthma, *1983*: Jan., 47
Collagen vascular disease, *1982*: Sept., 565–578
dermatomyositis, *1982*: Sept., 574, 575
lupus erythematosus, *1982*: Sept., 565–569
lung volume in, *1982*: Sept., 567, 568
presence of immunoglobulins, *1982*: Sept., 565, 566
roentgenographic findings in, *1982*: Sept., 567
mixed connective tissue disease, *1982*: Sept., 576
polymyositis, *1982*: Sept., 574, 575
pulmonary vasculitis and, *1982*: Sept., 615
rheumatoid arthritis, *1982*: Sept., 569–571
immunologic factors in, *1982*: Sept., 569, 570
sclerosis, progressive systemic, *1982*: Sept., 571–574
Sjögren's syndrome, *1982*: Sept., 574
Combined small cell lung carcinoma, pathology of, *1982*: May, 271
Co-morbidity, in staging lung cancer, *1982*: May, 295–296
Complement assays, for diagnosis of occupational lung disease, *1983*: Jan., 92–93
Complement system, role in activation of granulocytes, *1982*: Jan., 18
Compliance, left ventricular, PEEP and, *1983*: May, 181
pulmonary vascular, *1983*: May, 117
thoracic, *1983*: May, 109
vascular, hemodynamic significance, of, *1983*: May, 113–114
Computed tomography, for acute aortic disease, *1984*: June, 257–258
for emphysema, *1983*: Sept., 436–440
for hilar masses, *1984*: June, 374
for lung lesions, *1984*: June, 372–374
for mediastinal masses, *1984*: June, 374–376
for planning radiation therapy for lung cancer, *1982*: May, 342
for solitary pulmonary nodule, *1982*: May, 363
for staging bronchogenic carcinoma, *1982*: May, 339–343; *1984*: June, 274–275, 354–361
of chest wall, *1984*: June, 279
of lung, *1984*: June, **265–276**
of mediastinum, *1984*: June, **291–305**
indications for, *1984*: June, 291–303
scanning method for, *1984*: June, 291
of pleura, *1984*: June, **276–279**
Congenital heart disease, cardiopulmonary interactions in, *1983*: May, **219–232**
pulmonary hypertension with, *1983*: May, 210
Congestive heart failure, radiographic findings in, *1984*: June, 255–256
Connective tissue changes, in interstitial disease, *1982*: Sept., 460
Consciousness, in respiratory regulation, *1984*: Dec., 610–611
Contrast agents, for NMR studies, *1984*: June, 309
Contractile failure, muscular, *1984*: Mar., 24–25
Contrast angiography, in cor pulmonale, *1983*: May, 275
Cor pulmonale, *1983*: May, 269–273, 300
after pulmonary embolism, *1984*: Sept., 408, 434
cardiac glycosides in, *1983*: May, 122
cardiovascular function in, *1983*: May, **269–295**
COPD and, *1983*: May, **269–295**; *1984*: Mar., 129–131
in chronic bronchitis, *1983*: May, 203
in cystic fibrosis, *1983*: May, 203
in experimental emphysema, *1983*: Sept., 396
left ventricular function in, *1983*: May, 283–285
right ventricular function in, *1983*: May, 274–283
right ventricular hypertrophy with, *1983*: May, 106
therapy for, *1983*: May, 285
Coronary blood flow, during CPR, *1983*: May, 196

Coronary heart disease, pulmonary embolism after, right ventricular response to, *1984*: Sept., 431
Coronary insufficiency, effect on cardiac output, *1983*: May, 119
Corticosteroids, clearance of, *1984*: Dec., 671
clinical studies of, *1982*: Jan., 124–129
for asthma, *1984*: Dec., **669–683**
complications of, *1984*: Dec., 707–708
for emphysema, *1983*: Sept., 471
for severe asthma, *1984*: Dec., 631
withdrawal of, *1984*: Dec., 679–680
Cotton dust, respiratory effects of, immune factors in, *1983*: Jan., **63–70**
Cotton seed, as cause of occupational asthma, *1983*: Jan., 48
Cough, productive, and incidence of emphysema, *1983*: Sept., 333
Coumarin derivatives, for venous thromboembolic disease, *1984*: Sept., 387, 482–483
Counterpulsation balloons, positioning of, radiography for, *1984*: June, 263
CPAP, clinical characteristics of, *1982*: Jan., 80
complications of, *1982*: Jan., 81
for adult respiratory distress syndrome, *1982*: Jan., 79–81
Creola bodies, in sputum of asthmatics, *1984*: Dec., 569
CRIE. See *Crossed radioimmunoelectrophoresis*.
Critical care, diagnostic imaging in, *1984*: June, **247–264**
Critical pressure, pulmonary, *1983*: May, 129
Cromolyn, for asthma, *1984*: Dec., 687–688
Crossed immunoelectrophoresis, for demonstrating crude fungal extracts, *1983*: Jan., 24
for identifying fungal allergens, *1983*: Jan., 36–38
Crossed radioimmunoelectrophoresis, for demonstrating distinct fungal allergens, *1983*: Jan., 24
for identifying individual fungal allergens, *1983*: Jan., 36–38
Crotolaria spectabilis, pulmonary hypertension due to, *1983*: May, 204, 208–210
CT. See *Computed tomography*.
Cushing's disease, thromboembolic complications of, *1984*: Sept., 396
Cutting needle biopsy, for diagnosing lung cancer, *1982*: May, 326
Cyclophosphamide, interstitial lung disease and, *1982*: Sept., 526
Cystic fibrosis, allergic bronchopulmonary aspergillosis and, *1983*: Jan., 17
cor pulmonale in, *1983*: May, 203
pulmonary gas exchange in, *1983*: May, 155

D-antigen, elevated in adult respiratory distress syndrome, *1982*: Jan., 6
Delayed skin reaction, in occupational lung disease, *1983*: Jan., 86–87
Dermatomyositis, collagen vascular disorders and, *1982*: Sept., 574, 575
Dextran, in prevention of venous thromboembolic disease, *1984*: Sept., 397, 483
Diabetes, complicating management of asthma, *1984*: Dec., 701
Diagnostic imaging, in acute cardiopulmonary disease, *1984*: June, 247–264. See also under specific types, such as *Computed tomography*.
Diagnostic tests, efficacy of, *1984*: Sept., 440
Diaphragm, in asthma, *1984*: Dec., 613
in COPD, *1984*: Mar., 124
in emphysema, *1983*: Sept., 422–427
experimental, *1983*: Sept., 395
rupture of, ultrasound evaluation of, *1984*: June, 286, 288, 290
Diethylstilbestrol, for alpha-1-antitrypsin deficiency, *1983*: Sept., 370
Diffusing capacity, reduction, in interstitial disease, *1982*: Sept., 463
Digitalis, in cor pulmonale, *1983*: May, 286
Digital subtraction angiography, complications of, *1984*: June, 314
in pulmonary embolism, *1984*: Sept., 386, 472–476
in staging of bronchogenic carcinoma, *1984*: June, 357
of chest, *1984*: June, 313–328
of mediastinal masses, *1984*: June, 327
of pulmonary circulation, *1984*: June, 314–317
of thoracic aorta and branches, *1984*: June, 318–325
technique of, *1984*: June, 313–314
Digoxin, in COPD, *1984*: Mar., 136
Dihydroergotamine, in prevention of postoperative thromboembolic disease, *1984*: Sept., 484
Disseminated intravascular coagulation, as cause of adult respiratory distress syndrome, *1982*: Jan., 204
Diuretics, hemodynamic effects of, *1983*: May, 122
in COPD, *1983*: May, 285
Diurnal variation, in pulmonary function in asthmatics, *1984*: Dec., 576
Dopamine, effect on oxygen uptake, *1983*: May, 143
effect on ventricular function, *1983*: May, 264
Doppler ultrasonography, in diagnosis of venous thromboembolic disease, *1984*: Sept., 444–446
Dornhorst classification of chronic obstructive airways disease, *1983*: Sept., 333
Double immunodiffusion technique of Ouchterlony, *1983*: Jan., 89
Down's syndrome, lungs in, *1983*: Sept., 343
Drowning, as cause of adult respiratory distress syndrome, *1982*: Jan., 197
Drug overdose, associated with adult respiratory distress syndrome, *1982*: Jan., 205
hemodynamic monitoring in, *1983*: May, 246
DSA. See *Digital subtraction angiography*.
Ductus arteriosus, patent, circulatory pathology in, *1983*: May, 221–225
Durham spore sampler, *1983*: Jan., 30
Dusts, chemical, as cause of occupational asthma, *1983*: Jan., 49–51
inorganic, pulmonary disease and, immune factors in, *1983*: Jan., **3–14**
organic, as cause of occupational asthma, *1983*: Jan., 46–49
Dyspnea, cardiac, response to exercise testing, *1984*: Mar., 104
evaluation of, *1984*: Mar., **99–108**
exercise testing for, *1984*: Mar., **99–108**
exertional, determining cause of, *1984*: Mar., 178–179
in COPD, *1984*: Mar., 128
in idiopathic pulmonary fibrosis, *1984*: Mar., 149
in patients with emphysema, *1983*: Sept., 419
metabolic factors in, *1984*: Mar., 101

Ear oximetry, for monitoring oxygenation, *1982*: Jan., 187
Echocardiography, in cor pulmonale, *1983*: May, 278–279
Eczema, asthma and, *1984*: Dec., 560
Edema, airways, in asthma, *1984*: Dec., 568–569
pulmonary. See *Pulmonary edema*.
Effusion, pericardial, pressure changes with, *1983*: May, 107
radiographic appearance of, *1984*: June, 239–246
pleural, radiographic appearance of, *1984*: June, 252–253

Eicosanoids, *1984*: Dec., 673
effect of corticosteroids on, *1984*: Dec., 675
Elastase, neutrophil, role in emphysema, *1983*: Sept., 360–361
sources of, in humans, *1983*: Sept., 405–407
Elastase-antielastase, in pathogenesis of emphysema, *1983*: Sept., 405–412
Elastase emphysema, lung growth and, *1983*: Sept., 340, 342
Elastase inhibitors, role of, *1983*: Sept., 407–408
synthetic, experimental work with, *1983*: Sept., 408–410
for alpha-1-antitrypsin deficiency, *1983*: Sept., 370
Elastic recoil, of emphysematous lungs, *1983*: Sept., 345–348, 415–418
Elastin, damaged, reduced resynthesis of, after smoking, *1983*: Sept., 362
Electrolyte abnormalities, as complications of adult respiratory distress syndrome, *1982*: Jan, 178–179
ELISA, for detecting antibodies in hypersensitivity pneumonitis, *1983*: Jan., 58
for detecting fungal allergens, *1983*: Jan., 36
Embolism, air, with invasive hemodynamic monitoring, *1983*: May, 242
fat, as cause of adult respiratory distress syndrome, *1982*: Jan., 202–203
pulmonary, CT findings in, *1984*: June, 270, 272–273
hemodynamic effects of, *1983*: May, 120
radiographic findings in, *1984*: June, 252
venous air, associated with adult respiratory distress syndrome, *1982*: Jan., 205
Emotions, in asthma, *1984*: Dec., 595
Emphysema. See also specific types, e.g., *Paracicatricial emphysema*.
chronic airflow obstruction in, *1983*: Sept., 344–345
classification of, radiologic, *1983*: Sept., 434
clinical diagnosis of, *1983*: Sept., 331–335
clinical signs of, *1983*: Sept., 419–420
definition of, *1983*: Sept., 337–343
epidemiology of, *1983*: Sept., **351–358**
exercise arterial blood gases in, *1984*: Mar., 127
experimental, *1983*: Sept., **389–403**
pulmonary mechanics in, *1983*: Sept., 395
genetic principles in, *1983*: Sept., **377–387**
interstitial, radiographic appearance of, *1984*: June, 254
left ventricular function in, *1983*: May, 283–284
medical management of, *1983*: Sept., **465–482**
oxygen therapy in, *1983*: May, 300–303
pathogenesis of, *1983*: Sept., 334
pathologic classification of, *1983*: Sept., 330–331
pathology of, *1983*: Sept., **337–350**
pathophysiology of, *1983*: Sept., **413–420**
PEEP and, *1982*: Jan., 93
physiologic correlations in, *1983*: Sept., 333
prevention of, *1983*: Sept., 335
pulmonary artery pressure and pulmonary vascular resistance, *1983*: May, 270
pulmonary dysfunction associated with, *1983*: Sept., 343–348
pulmonary hypertension and, *1983*: May, 298–300
radiology of, *1982*: Jan., 93; *1983*: Sept., **433–442**
risk factors in, *1983*: Sept., 356–357
surgical management of, *1983*: Sept., **443–463**
symposium on, *1983*: Sept., **329–484**
ventilation in, *1984*: Mar., 128
Empyema, ultrasound evaluation of, *1984*: June, 286–287
Endobronchial lesion, diagnosis of, *1984*: June, 372
Endocrine function, effects of physical training on, *1984*: Mar., 9
Endotoxin, in development of emphysema, *1983*: Sept., 398
Endotracheal tube, positioning of, radiography for, *1984*: June, 262
Endurance exercise, carbohydrate loading in, *1984*: Mar., 73
cardiac hypertrophy with, *1984*: Mar., 68
cardiac output in, *1984*: Mar., 68
cardiovascular responses to, *1984*: Mar., 67–68
energy utilization in, *1984*: Mar., 69
environmental factors in, *1984*: Mar., 70
forced vital capacity in, *1984*: Mar., 65
metabolic requirements of, *1984*: Mar., 64
minute ventilation in, *1984*: Mar., 65
muscle enzyme activity and, *1984*: Mar., 69
muscle fatigue in, *1984*: Mar., 69
muscle function in, *1984*: Mar., 68–70
muscle injury and, *1984*: Mar., 70
physiology of, *1984*: Mar., **63–76**
respiratory changes in, *1984*: Mar., 65
respiratory responses in, *1984*: Mar., 64–67
stroke volume in, *1983*: Mar., 68
training for, *1984*: Mar., 72–73. See also *Physical training*.
Environment, control of, for asthmatics, *1984*: Dec., 604, 704
Enzymes, in cotton dust, as cause of byssinosis, *1983*: Jan., 65
Epidemiology, of asthma, *1984*: Dec., **557–565**
of emphysema, *1983*: Sept., **351–358**
Epinephrine, as prototypical bronchodilator, *1984*: Dec., 659
effect on oxygen uptake, *1983*: May, 143
Equal pressure point concept, in airflow obstruction, *1984*: Dec., 574
Esophageal reflux, complicating management of asthma, *1984*: Dec., 704
Esophagrams, barium, in staging bronchogenic carcinoma, *1984*: June, 357
Esophagus, air in, radiographic appearance of, *1984*: June, 228–230
carcinoma of, CT staging of, *1984*: June, 298–299
Estrogen therapy, risk of pulmonary embolism from, *1984*: Sept., 395
Exercise. See also *Physical training*.
anaphylaxis due to, *1984*: Mar., 116
asthma induced by, *1984*: Mar., 109–119; Dec., 581–582, 593–594
breathing frequency during, *1984*: Mar., 36, 40
cardiopulmonary response to, *1983*: May, **101–110**
circulating blood volume during, *1984*: Mar., 17
effects of training on, *1984*: Mar., 58
effects on plasma lipoproteins, *1984*: Mar., 9
effects on protein metabolism, *1984*: Mar., 5
effects on pulmonary gas exchange, *1983*: May, 155–158
endurance, physiology of, *1984*: Mar., **63–76.** See also *Endurance exercise*.
energy determinants in, *1984*: Mar., 55–56
energy utilization during, *1984*: Mar., 56, 64
enhanced glucose utilization during, *1981*: Mar., 4–5
for patients with emphysema, *1983*: Sept., 477–478
frequency and depth of respirations during, *1984*: Mar., 35–38
fuel-hormone metabolism during, *1984*: Mar., **3–11**
gas transport and, *1984*: Mar., 174
hormonal response to, *1984*: Mar., 6–7
hyperthermia during, *1984*: Mar., 13–20
in hot weather, *1984*: Mar., 16–19
lactate and bicarbonate changes during, *1984*: Mar., 80

lactic acid production in, *1984*: Mar., 77–78
minute ventilation during, *1984*: Mar., 36
phases of fuel consumption during, *1984*: Mar., 4
physiologic responses in asthmatics, *1984*: Mar., 109–111. See also *Bronchial asthma*.
pulmonary and systemic hemodynamic variables during, *1983*: May, 271
pulmonary circulation during, *1983*: May, 103
right ventricular ejection fraction during, *1983*: May, 280
pulmonary ventilation during, *1984*: Mar., 35–38
recovery period after, *1984*: Mar., 7–8
role in development of emphysema, *1983*: Sept., 397
role of maximal oxygen uptake in, *1984*: Mar., **51–62**
sex, age, and body composition and, *1984*: Mar., 57
temperature regulation during, *1984*: Mar., 13–20
tidal volume during, *1984*: Mar., 36–37
ventilatory pump in, *1984*: Mar., **35–49**
venous return curve and, *1983*: May, 116
Exercise impairment, criteria for, *1984*: Mar., 164
in COPD, *1984*: Mar., **121–143**
Exercise performance, maximal, in idiopathic pulmonary fibrosis, *1984*: Mar., 149
Exercise testing, adult normal values in, *1984*: Mar., **89–98**
airflow obstruction and, *1984*: Mar., 103, 105
anaerobic threshold measurement in, *1984*: Mar., **77–88**
arterial blood gases during, *1984*: Mar., 93
cardiac dyspnea and, *1984*: Mar, 104
cardioacceleration on, *1984*: Mar., 194–195
criteria for impairment on, *1984*: Mar., 164
detection of malingering on, *1984*: Mar., 166
excessive metabolic acidosis on, *1984*: Mar., 196
heart rate during, *1984*: Mar., 91
in aortic insufficiency, *1984*: Mar., 183
in asbestosis, *1984*: Mar., 158
in cardiopulmonary disease, *1984*: Mar., **173–187**
in circulatory failure, *1984*: Mar., 175–179
in COPD, *1984*: Mar., 132–133, 185–187
in dyspnea, *1984*: Mar., **99–108**
in evaluating occupational impairment, *1984*: Mar., 165–167
in heart disease, *1984*: Mar., **181–185**
in interstitial lung disease, *1984*: Mar., 103, **145–156**, 182
in mitral stenosis, *1984*: Mar., 176
in mitral valve disease, *1984*: Mar., 183–184
in obese patient, *1984*: Mar., 193
in occupational lung diseases, *1984*: Mar., **157–171**
in pneumoconioses, *1984*: Mar., 158, 161
in pulmonary vascular disease, *1984*: Mar., 103, 177
in pulmonary venous hypertension, *1984*: Mar., 176
in sarcoidosis, *1984*: Mar., 149–152
interpretation in respiratory disease, *1984*: Mar., **189–206**
maximal, *1984*: Mar., 193
oxygen consumption in, *1984*: Mar., 190–192
oxygen uptake during, *1984*: Mar., 91
pattern of ventilation in, *1984*: Mar., 93
protocols for, *1984*: Mar., 103, 175
in occupational lung disease, *1984*: Mar., 161
respiratory muscle weakness and, *1984*: Mar., 103, 106
submaximal, *1984*: Mar., 162, 198
ventilatory limitation on, *1984*: Mar., 196–197
Exercise tolerance, heart disease and, *1984*: Mar., 181–185
in sarcoidosis, *1984*: Mar., 151
training. See *Physical training*.
Exertional dyspnea, determining cause of, *1984*: Mar., 177–179
Extrathoracic surgery, radiography after, *1984*: June, 260

Farmer's lung, *1982*: Sept., 506, 507
nitrous oxide inhalation and mycotoxicosis, *1982*: Sept., 506
other diseases and related patterns of exposure, *1982*: Sept., 507
Fat embolism, as cause of adult respiratory distress syndrome, *1982*: Jan., 202–203
Fatigue, electromyographic changes during, *1984*: Mar., 30
muscular, *1984*: Mar., **21–34**
neuromuscular, *1984*: Mar., 21–23
of respiratory muscles, *1984*: Mar., 33
Fatigue threshold, *1984*: Mar., 21
Fenestrae, in emphysematous lungs, *1983*: Sept., 339–340
Fetal circulation, persistent, *1983*: May, 212–215
Fever, effects on peripheral oxygen uptake, *1983*: May, 143
Fiberoptic bronchoscopy. See *Bronchoscopy, fiberoptic*.
Fibrinolytic agents, in management of acute pulmonary embolism, *1984*: Sept., 409
Fibrosis, pulmonary, idiopathic, immunologic methods for diagnosis, *1983*: Jan., 78–79
Fibrotic gene, *1982*: Sept., 635, 636
Filling pressure gradient, of right heart, *1983*: May, 102
Fissures, pulmonary, radiographic appearance of, *1984*: June, 220–228
Fistula, bronchopleural, vs. lung absencess, on CT, *1984*: June, 277–279
Flow-volume curves, in COPD, *1984*: Mar., 122
Fluid filtration rate, pulmonary, *1983*: May, 132–135
Fluid management, of severe asthma, *1984*: Dec., 628–629
Forced vital capacity, in endurance exercise, *1984*: Mar., 65
Formaldehyde, as cause of occupational asthma, *1983*: Jan., 50
Formalin, perfusion of lung with, for diagnosing emphysema, *1983*: Sept., 352
Fuel(s). See *Body fuels*.
Fuel-hormone metabolism, exercise and, *1984*: Mar., **3–11**
Functional residual capacity, in adult respiratory distress syndrome, *1982*: Jan., 10–11
in infants and children, *1983*: May, 220
Fungi, cross-reactivity of, *1983*: Jan., 25
respiratory allergy and, *1983*: Jan., **23–41**
taxonomy of, *1983*: Jan., 25–26

Gallium scanning, for detecting metastases of lung cancer, *1982*: May, 345–346
in staging of bronchogenic carcinoma, *1984*: June, 357–358
interstitial disease and, *1982*: Sept., 467, 468
Gas(es), blood. See *Blood gases*.
chemical, as cause of occupational asthma, *1983*: Jan., 49–51
Gas exchange, cardiac function and, *1983*: May, **149–159**. See also *Pulmonary gas exchange*.
in adult respiratory distress syndrome, *1982*: Jan., **57–67**
in asthma, *1984*: Dec., 578–579
in emphysema, *1983*: Sept., 418–419
monitoring of, *1982*: Jan., 185
Gas exchange ratio, respiratory, *1983*: May, 105
Gas transport, exercise and, *1984*: Mar., 174
Gas transport system, *1983*: May, **101–110**
Gastric contents, aspiration of, *1982*: Jan., 197
Gel radial immunodiffusion, for detection of occupational lung disease, *1983*: Jan., 88

Giant cell lung carcinoma, pathology of, *1982*: May, 282–283
Glomerulonephritis, membranoproliferative, alpha-1-antitrypsin deficiency and, *1983*: Sept., 368
Glucocorticoids, chemistry of, *1984*: Dec., 669
for treating adult respiratory distress syndrome and shock, *1982*: Jan., **121–132**
Glucose, utilization during exercise, *1984*: Mar., 4–5
Glycosides, cardiac, in cor pulmonale, *1983*: May, 122
Goiter, CT evaluation of, *1984*: June, 293
Goodpasture's syndrome, *1982*: Sept., 593–598
Grain, as cause of occupational asthma, *1983*: Jan., 48
Gram-negative sepsis, adult respiratory distress syndrome and, *1982*: Jan., 19
Granulocytes, role in lung injury, *1982*: Jan., 17–20
Granuloma, midline, *1982*: Sept., 612, 613
Granulomatosis, allergic, *1982*: Sept., 612–614
bronchocentric, *1984*: Sept., 614
granulomatous, *1982*: Sept., 607, 608
Granulomatous vasculitis, *1982*: Sept., 607, 608
Great veins, collapsibility of, effects on cardiac output, *1983*: May, 113–115
Greenfield vena cava filter, in treatment of pulmonary embolism, *1984*: Sept., 497–499

Heart, changes in, with PEEP, *1982*: Jan., 64
compliance of, hemodynamic effects of, *1983*: May, 117
congenital disease of, *1983*: May, 210, **219–232**
function of. See *Cardiac function*.
functional integration with lungs, *1983*: May, 101
hypertrophy of, endurance exercise and, *1984*: Mar., 68
interdependence of ventricles, *1983*: May, 105–108, 164–165, 171–174
interventricular septum of, *1983*: May, 106–107
intrapericardial pressure on, *1983*: May, 107
muscle fibers of, *1983*: May, 105–106
NMR studies of, *1984*: June, 310–311
output of. See *Cardiac output*.
oxygen extraction of, *1983*: May, 104
parasympathetic stimulation of, *1983*: May, 119
right, filling pressure gradient of, *1983*: May, 102
in circulatory homeostasis, *1983*: May, 103
Starling's law of, *1983*: May, 119, 309
ventricular geometry of, *1983*: May, 165, 173
Heart disease, as risk factor for pulmonary embolism, *1984*: Sept., 393
complicating management of asthma, *1984*: Dec., 698–700
congenital, cardiopulmonary interactions in, *1983*: May, **219–232**
pulmonary hypertension with, *1983*: May, 210
pulmonary. See *Cor pulmonale*.
pulmonary hypertension with, *1983*: May, 297–298
response to exercise in, *1984*: Mar., **181–185**
Heart failure, definition of, *1983*: May, 105
effects on pulmonary gas exchange, *1983*: May, 153
exercise testing for, *1984*: Mar., 175–179
left-sided, pulmonary venous hypertension with, *1983*: May, 103
Heart rate, during exercise testing, *1984*: Mar., 91
in endurance exercise, *1984*: Mar., 68
oxygen consumption and, *1984*: Mar., 190
Heat loss, respiratory, in exercise-induced asthma, *1984*: Mar., 111
Hematocrit, postnatal decline in, *1983*: May, 221
Hematologic disease, risk of pulmonary embolism in, *1984*: Sept., 396
Hemodynamic monitoring, in adult respiratory distress syndrome, *1982*: Jan., **157–169**
invasive, *1983*: May, **233–249**
complications of, *1983*: May, 240–244
indications for, *1983*: May, 244–246
technique of, *1983*: May, 233–235
Hemorrhage, gastrointestinal, as complication of adult respiratory distress syndrome, *1982*: Jan., 146–147
Hemosiderosis, pulmonary, idiopathic, *1982*: Sept., 600–602
familial, *1982*: Sept., 638
Heparin, for deep venous thrombosis, *1984*: Sept., **542–545**
for venous thromboembolic disease, *1984*: Sept., 386, 479–481
incidence of pulmonary emboli and, *1982*: Jan., 143
subcutaneous, in prevention of venous thromboembolic disease, *1984*: Sept., 387, 398
Heredity, in development of emphysema, *1983*: Sept., **377–387**
High-frequency positive-pressure ventilation, for adult respiratory distress syndrome, *1982*: Jan., 81–83
Hilum, CT evaluation of, *1984*: June, 272, 274
mass of, diagnosis of, *1984*: June, 374
needle aspiration biopsy of, *1984*: June, **365–377**
NMR studies of, *1984*: June, 310
Hirst spore trap, *1983*: Jan., 31
Histamine, levels of, in cotton workers, *1983*: Jan., 67–68
Histiocytosis-X, primary pulmonary, *1982*: Sept., **643–653**
causes of, *1982*: Sept., 645, 646
cells in, *1982*: Sept., 645
chest roentgenogram in, *1982*: Sept., 647, 648
pathophysiology of, *1982*: Sept., 648, 649
role of biopsy in, *1982*: Sept., 649
symptoms of, *1982*: Sept., 646
Histiocytosis-X cells, *1982*: Sept., 466
Histocompatibility antigen, coal workers' pneumoconiosis and, *1983*: Jan., 11
Histology, importance in staging lung cancer, *1982*: May, 294–295
HLA, pulmonary sarcoidosis and, *1982*: Sept., 550
Hormones, adrenocortical, ectopic production in lung cancer, *1982*: May, 308–310
antidiuretic, inappropriate secretion of, *1982*: May, 310–312
effects of physical training on, *1984*: Mar., 6–9
growth, increased concentration in lung cancer, *1982*: May, 313
Hot weather, exercise in, *1984*: Mar., 16–19
Hughes-Stovin syndrome, *1982*: Sept., 616
Human leukocyte antigen, pulmonary sarcoidosis and, *1982*: Sept., 550
"Humidifier lung," *1982*: Sept., 508; *1983*: Jan., 55–57
Hydralazine, *1983*: May, 256, 312
Hydrocarbons, lung cancer and, *1982*: May, 224–225
Hydrochloric acid, role in aspiration pneumonitis, *1982*: Jan., 25–29
Hydroxychloroquine, in prevention of postoperative thromboembolic disease, *1984*: Sept., 484
Hyperoxia, pulmonary, *1982*: Jan., **109–119**
response to, in experimental emphysema, *1983*: Sept., 397
tolerance to, *1982*: Jan., 111–112
Hypersensitivity pneumonitis, *1982*: Sept., **503–519**
airways, immunologic factors in, *1982*: Sept., 511–515
byssinosis, *1982*: Sept., 507, 508
chronic disease, signs of, *1982*: Sept., 510
farmer's lung, *1982*: Sept., 506, 507
humidifier lung, *1982*: Sept., 508
immune factors in, *1983*: Jan., **55–62**

immunologic methods for diagnosis, *1983*: Jan., 75–78
immunopathogenesis of, *1982*: Sept., 515–517
lymphocytic-granuloma tissue response in, *1982*: Sept., 517
mistaken for asthma, *1984*: Dec., 697
pigeon breeder's lung, *1982*: Sept., 508, 509
Hypertension, pulmonary. See *Pulmonary hypertension.*
pulmonary venous, exercise testing in, *1984*: Mar., 176
thromboembolic, *1983*: May, 211–212
Hyperthermia, during exercise, *1984*: Mar., 13–20
Hyperventilation, acute, mistaken for asthma, *1984*: Dec., 695–696
after pulmonary embolism, *1984*: Sept., 417
in exercise-induced asthma, *1984*: Mar., 111
Hypocarbia, arterial, with acute pulmonary embolism, *1984*: Sept., 417
Hypotension, as complication of adult respiratory distress syndrome, *1982*: Jan., 149
Hypoxemia, after pulmonary embolism, *1984*: Sept., 422–423
in adult respiratory distress syndrome, *1982*: Jan., 10, 58, 69, 198
in asthma, *1984*: Dec., 578–579
in infants and children, *1983*: May, 228
sleep, *1983*: May, 303–306
systemic arterial, cardiac index and, *1984*: Sept., 424
pulmonary artery mean pressure and, *1984*: Sept., 423
Hypoxia, *1983*: May, 203–208
acute, hemodynamic effects of, *1983*: May, 120–121
venous return curves with, *1983*: May, 120–121
adaptive responses to, *1983*: May, 143
as stimulant to respiration, *1984*: Dec., 611–613
chronic, of altitude, *1983*: May, 297
effects on pulmonary vascular resistance, *1983*: May, 131–133
hypobaric, mean pulmonary artery pressure in, *1983*: May, 205
hypoxic, *1983*: May, 139–144
in anemia, *1983*: May, 139–140
oxyhemoglobin dissociation curve in, *1983*: May, 140–141
pulmonary pressor response to, *1983*: May, 203
site of action of, *1983*: May, 132–133

I-125 fibrinogen scanning, in diagnosis of venous thromboembolic disease, *1984*: Sept., 386, 397, 446–447, 450–452
Iatropy, in staging lung cancer, *1982*: May, 295
Idiopathic pulmonary fibrosis, *1982*: Sept., **579–592**; *1984*: Mar., 146–148
arterial blood gases in, *1984*: Mar., 149
corticosteroid therapy in, *1982*: Sept., 587–590
dyspnea of, *1984*: Mar., 149
familial, *1982*: Sept., 636
humoral immune system, *1982*: Sept., 586
lung physiology in, *1982*: Sept., 581–583
maximal exercise performance in, *1984*: Mar., 149
methods of staging, *1982*: Sept., 586, 587
pathology of, *1982*: Sept., 584, 585
roentgenographic features, *1982*: Sept., 581
role of biopsy, *1982*: Sept., 583, 584
treatment response in, *1984*: Mar., 148
Imaging, diagnostic, in acute cardiopulmonary disease, *1984*: June, 247–264. See also under specific types, such as *Computed tomography.*
radionuclide, *1983*: May, 275
thallium-201, *1983*: May, 282
Immediate skin reaction, in occupational lung disease, *1983*: Jan., 85–86
Immune complex assays, for diagnosis of occupational lung disease, *1983*: Jan., 91–92
Immune factors, in pulmonary disease, symposium on, *1983*: Jan., **1–95**
Immunity, categories of, *1984*: Dec., 599–600
Immunoadjuvant therapy, for lung cancer, *1982*: May, **432–441**
Immunoblastic lymphadenopathy, *1982*: Sept., 622–625
Immunocompetence, depressed, as complication of adult respiratory distress syndrome, *1982*: Jan., 150–151
in adult respiratory distress syndrome, nutrition and, *1982*: Jan., 102
Immunodiffusion techniques, for diagnosis of occupational lung disease, *1983*: Jan., 88–90
Immunoelectrophoresis, for identification of environmental antigens, *1983*: Jan., 90
Immunoincompetence, in lung cancer, *1982*: May, 424–426
Immunologic techniques, for diagnosing occupational lung disease, *1983*: Jan., 85–95
Immunopathogenesis, of interstitial disease, *1982*: Sept., 459
Immunotherapy, for asthma, *1984*: Dec., 604
lung cancer, rationale for, *1982*: May, 423–424
for small cell lung cancer, *1982*: May, 395
Impedance plethysmography, in diagnosis of venous thromboembolic disease, *1984*: Sept., 386, 397, 441–444, 450–452
Infant(s), cardiopulmonary function in, *1983*: May, 219–221
left-to-right shunts in, *1983*: May, 221–227
newborn, persistent pulmonary hypertension in, *1983*: May, 212–215
right-to-left shunts in, *1983*: May, 227–230
Infection, after pulmonary artery pressure monitoring, *1983*: May, 243
as complication of adult respiratory distress syndrome, *1982*: Jan., 178
bronchopulmonary, bacterial colonization and, *1982*: Jan., **133–142**
nosocomial, as complication of adult respiratory distress syndrome, *1982*: Jan., 149–150
pulmonary, pneumonia with, *1984*: June, 250–252
role in aspiration pneumonitis, *1982*: Jan., 32
respiratory tract, asthma and, *1984*: Dec., 561, 595
chronic, complicating management of asthma, *1984*: Dec., 702
in children, *1984*: Dec., 638–639
thoracic, CT evaluation of, *1984*: June, 270, 272, 301
Infiltrative lung diseases, lymphocytic, *1982*: Sept., **619–634**
Inflammation, in severe asthma, *1984*: Dec., 624
mucosal, in asthma, *1984*: Dec., 567–568
with corticosteroid therapy, *1984*: Dec., 674
Inhalation challenge testing, with fungi, *1983*: Jan., 34
Inorganic dusts, pulmonary disease and, immune factors in, *1983*: Jan., **3–14**
Inspiration, forced, *1983*: May, 106
Interalveolar wall distance, in emphysematous lungs, *1983*: Sept., 337, 345–346
Intermediate cell subtype, of small cell carcinoma of lung, *1982*: May, 271
Intermittent positive pressure breathing, for severe asthma, *1984*: Dec., 629
left ventricular function and, *1983*: May, 176
pulmonary arterial blood flow with, *1983*: May, 176
transmural aortic pressure changes with, *1983*: May, 179

Intermittent positive pressure ventilation, (IPPV), effects on pleural pressure, *1983*: May, 161–162
hemodynamic effects of, *1983*: May, 176–183
International Labour Organization modification of radiographic classification of pneumoconioses, *1984*: June, 332–344
Interstitial collagens, alteration of, *1982*: Sept., 460
Interstitial fibrosis, altered gas exchange in, *1984*: Mar., 145–149
diffuse, as complication of adult respiratory distress syndrome, *1982*: Jan., 144–145
Interstitial lung diseases, collagen-vascular disorders and, *1982*: Sept., **565–578**
drug-induced, *1982*: Sept., **521–536**. See also under individual drugs.
exercise testing in, *1984*: Mar., 103, **145–156,** 182
indications for, *1984*: Mar., 152–155
heredity and, *1982*: Sept., **635–641**
inherited, arteritis, familial granulomatous, *1982*: Sept., 639
familial idiopathic pulmonary fibrosis, *1982*: Sept., 636
hemosiderosis, familial idiopathic pulmonary, *1982*: Sept., 638
metabolic storage diseases, *1982*: Sept., 638, 639
neurofibromatosis, *1982*: Sept., 638
pneumonitis, familial lymphoid interstitial, *1982*: Sept., 638
sarcoidosis, *1982*: Sept., 639
tuberous sclerosis, *1982*: Sept., 636, 637
introduction to, *1982*: Sept., **457–473**
oxygen transport in, *1983*: May, 105
pathology of, *1982*: Sept., **491–502**
radiology of, *1982*: Sept., **475–484**
surgical approach to, *1982*: Sept., **485–490**
symposium on, *1982*: Sept., **457–653**
Interstitial pneumonitis, plasma cell, *1982*: Sept., 625–627
Interventricular septum, of heart, *1983*: May, 106–107
Intrapericardial pressure, *1983*: May, 107
Intrapleural pressure, control of, *1983*: May, 108–109
Intrathoracic pressure, *1983*: May, 107
in COPD, *1983*: May, 284
Intravascular transmural pressure, measurement of, *1983*: May, 165
IPPB. See *Intermittent positive-pressure breathing*.
Isopropyl oil, lung cancer and, *1982*: May, 225

Kidney, aerobic capacity of, *1983*: May, 104
Kim-Ray filter, in prevention of recurrent pulmonary embolism, *1984*: Sept., 404, 406

Lactate, blood level of, changes in exercise, *1984*: Mar., 81–83
Lactic acid production, in exercise, *1984*: Mar., 77–78
Large cell lung carcinoma, pathology of, *1982*: May, 280–282
Lavage, bronchial, for severe asthma, *1984*: Dec., 632
bronchoalveolar. See *Bronchoalveolar lavage*.
Left-to-right shunts, respiratory complications of, *1983*: May, 222–225
sites of respiratory compromise in, *1983*: May, 226
therapeutic approach to, *1983*: May, 225–227
Left ventricular afterload, *1983*: May, 170–172
Left ventricular compliance, PEEP and, *1983*: May, 181
Left ventricular ejection fraction, in COPD, *1984*: Mar., 130
Left ventricular failure, mistaken for asthma, *1984*: Dec., 696
Left ventricular function, *1983*: May, 168–171
in COPD, *1983*: May, 168, 174–176, 283–285
in cor pulmonale, *1983*: May, 283–285
in emphysema, *1983*: May, 283–284
in respiratory failure, *1983*: May, 253–256
IPPV and, *1983*: May, 176
right ventricular overload and, *1984*: Sept., 430
Levamisole, for immunotherapy of lung cancer, *1982*: May, 433–434
Lipid(s), muscle metabolism of, *1984*: Mar., 8
Lipodermatosclerosis, *1984*: Sept., 537
Lipomatosis, mediastinal, CT evaluation of, *1984*: June, 292
Lipoproteins, plasma, effects of exercise on, *1984*: Mar., 9
Liver disease, alpha-1-antitrypsin deficiency and, *1983*: Sept., 367–368
Lobar collapse, radiographic findings in, *1984*: June, 213–220
Lobectomy, for lung carcinoma, *1982*: May, 373–375
radiographic changes after, *1984*: June, 258
Low viscosity bolus technique, to assess pulmonary vascular resistance, *1983*: May, 131
Lung(s). See also *Pulmonary*.
antibacterial defenses of, *1982*: Jan., 138–139
biopsy, open, *1982*: Sept., 486, 487, 495
blood flow through, *1983*: May, 102–103
cancer of. See *Lung cancer*.
carcinoma of. See specific types, as *Bronchogenic carcinoma*.
chronic diffuse infiltrative disease of, *1984*: June, **329–344**
contusion of, as cause of adult respiratory distress syndrome, *1982*: Jan., 206
CT of, *1984*: June, **265–276**
dead space of, Bohr, *1984*: Sept., 418
disease, occupational. See *Occupational lung diseases*, and specific disorders and causative agents.
dysfunction of, associated with emphysema, *1983*: Sept., 343–348
edema of, *1983*: May, 134, 153, 253–256
emphysematous, elastic recoil of, *1983*: Sept., 345–348
symposium on, *1983*: Sept., **329–484**
fibrotic reactions. See *Pulmonary fibrosis*.
fluid filtration rate of, *1983*: May, 135
functional integration with heart, *1983*: May, 101, 108–109, **149–159**
gas exchange in, cardiac function and, *1983*: May, **149–159**
hyperinflation of, reflexes associated with, *1983*: May, 163
infections of, CT evaluation of, *1984*: June, 270
pneumonia with, *1984*: June, 250–252
inflation of, effect on pulmonary vascular resistance, *1983*: May, 133–136
for diagnosing emphysema, *1983*: Sept., 352
humoral effects of, *1983*: May, 163
mechanical effects of, *1983*: May, 163
pulmonary pressure-flow curve and, *1983*: May, 132
injury to, granulocyte-arachidonate interactions in, *1982*: Jan., 20–21
granulocytes and, *1982*: Jan., 17–20
mechanisms of, *1982*: Jan., **9–24**
microvascular, *1982*: Jan., 10
role of alpha-1-antitrypsin in, *1983*: Sept., 360–363
overinflation of, in severe asthma, *1984*: Dec., 624
tumors of, NMR studies of, *1984*: June, 310
ventilation-perfusion scanning of, in diagnosis of pulmonary embolism, *1984*: Sept., 386

Lung biopsy, open, for diagnosing diffuse infiltrative pulmonary disease, *1983*: Jan., 75
Lung cancer, air pollution and, *1982*: May, 223
biology of, *1982*: May, 234–236, 292–293
clinically apparent, *1982*: May, 230
cytologic classification, *1982*: May, 234
diagnostic techniques for, *1982*: May, **321–329**
early detection of, *1982*: May, 230–231
epidemiology and etiology of, *1982*: May, **219–228**
genetic factors in, *1982*: May, 220–221
geographic variations in, *1982*: May, 219–220
histologic classification, *1982*: May, 234
immunoadjuvant therapy for, *1982*: May, **423–441**
immunoincompetence in, *1982*: May, 424–426
natural history of, *1982*: May, **229–241**
occupational causes of, *1982*: May, 223–226
pathology of, *1982*: May, **257–289**
pleural effusion in, *1982*: May, **443–452**
preclinical phase, *1982*: May, 229–230
early manifestations of, *1982*: May, 248–250
prognostic factors, *1982*: May, 236–237
radiologic presentation, *1982*: May, 232
second primary tumors in, *1982*: May, 231
pathology of, *1982*: May, 283–284
small cell. See *Small cell lung cancer*.
staging of, *1982*: May, **291–305**, 337–348; *1984*: June, **351–363**
CT for, *1984*: June, 274–275
prospective, *1982*: May, 235–236
symposium on, *1982*: May, **219–452**
symptoms and physical findings, *1982*: May, 233–234
tobacco and, *1982*: May, 222–223
tumor antigens in, *1982*: May, 426–427
Lung carcinoma, complications of, radiotherapeutic management of, *1982*: May, **415–421**
non–small cell, chemotherapy for, *1982*: May, **399–414**
radiation therapy for, *1982*: May, **399–414**
primary, imaging methods in, *1982*: May, **331–351**
radiographic manifestations of, *1982*: May, 331–337
staging of, *1982*: May, 337–348
surgery for, *1982*: May, **369–387**
Lung compliance, decreased, in adult respiratory distress syndrome, *1982*: Jan., 10–11
with hyperoxia, *1982*: Jan., 114
in COPD, *1984*: Mar., 121
increased, with PEEP, *1982*: Jan., 73
Lung disease, chronic diffuse infiltrative, *1984*: June, **329–344**
modified International Labour Organization classification for, *1984*: June, 329–344
chronic obstructive. See *Chronic obstructive pulmonary disease (COPD)*.
immune factors in, symposium on, *1983*: Jan., **1–95**
interstitial, oxygen transport in, *1983*: May, 105
Lung lesion(s). See specific types of lesions.
Lung parenchyma, changes in, in adult respiratory distress syndrome, *1982*: Jan., **35–56**
Lung perfusion, abnormalities in, causes of, *1984*: Sept., 458
frequency of pulmonary embolism with, *1984*: Sept., 460
scintigraphic assessment of, *1984*: Sept., 457–458
Lung volume(s), *1983*: May, 109
decreased, in interstitial disease, *1982*: Sept., 461
effect on pulmonary vascular resistance, *1983*: May, 163
in asthma, *1984*: Dec., 577–578
in COPD, *1984*: Mar., 121
in emphysema, *1983*: Sept., 414–415
Lupus erythematosus, *1982*: Sept., 565–569
Lymph nodes, hilar, CT evaluation of, *1984*: June, 274
mediastinal, CT evaluation of, *1984*: June, 296–297
Lymphangiography, associated with adult respiratory distress syndrome, *1982*: Jan., 206
Lymphocytes, in bronchoalveolar lavage fluid, *1983*: Jan., 73–74
Lymphocytic infiltrative lung diseases, *1982*: Sept., **619–634**
Lymphocytic interstitial pneumonitis, *1982*: Sept., 619–622
Sjögren's syndrome and, *1982*: Sept., 620, 622
Lymphomatoid granulomatosis, *1982*: Sept., 611, 612, 627–631

Macrophage, alveolar, as source of elastase, *1983*: Sept., 398, 406
in asbestosis, *1983*: Jan., 4
in bronchoalveolar lavage fluid, *1983*: Jan., 72–73
Malingering, on exercise testing, *1984*: Mar., 166
Marathon runners, airway obstruction in, *1984*: Mar., 67
heart rate in, *1984*: Mar., 68
maximal oxygen uptake in, *1984*: Mar., 59, 64
metabolic requirements in, *1984*: Mar., 64
muscle function in, *1984*: Mar., 68–70
oxygen requirements of, *1984*: Mar., 55–57
physiology of, *1984*: Mar., **63–76**
respiratory responses in, *1984*: Mar., 64–67
Marker substances, produced by bronchogenic carcinomas, *1982*: May, **307–320**
Maximal cardiac output, *1984*: Mar., 53
Maximal oxygen uptake, *1983*: May, 104
circulatory factors in, *1984*: Mar., 53–54
determinants of, *1984*: Mar., 52–55
determination of, *1984*: Mar., 52
during exercise testing, *1984*: Mar., 92
in COPD, *1984*: Mar., 125
in marathon runners, *1984*: Mar., 59, 64
muscle metabolism and, *1984*: Mar., 54
role in exercise performance, *1984*: Mar., **51–62**
Maximum ventilatory capacity, in COPD, *1984*: Mar., 122
Mean circulatory pressure, *1983*: May, 104
Mean systemic pressure, *1983*: May, 112, 114, 117
Mechanical ventilation, for patients with emphysema, *1983*: Sept., 476
for severe asthma, *1984*: Dec., 629–630
Mediastinoscopy, anterior, for staging lung cancer, *1982*: May, 356
cervical, for staging lung cancer, *1982*: May, 355
of hilar masses, *1984*: June, 374
of lung lesions, *1984*: June, 372–374
of mediastinal masses, *1984*: June, 374–376
role in lung cancer, *1982*: May, **353–359**
staging transcervical, of mediastinal lymph nodes, *1984*: June, 358
vs. needle aspiration biopsy, for bronchogenic carcinoma, *1984*: June, 371
Mediastinotomy, anterior, for staging lung cancer, *1982*: May, 355–356
role in lung cancer, *1982*: May, **353–359**
Mediastinum, CT evaluation of, *1984*: June, 274–275, **291–305**
indications for, *1984*: June, 291–303
method of, *1984*: June, 291
infection of, CT evaluation of, *1984*: June, 301
mass of, with lung lesion, *1984*: June, 374–376
DSA of, *1984*: June, 327
needle aspiration biopsy of, *1984*: June, **365–377**
without associated lung lesion, *1984*: June, 376
NMR studies of, *1984*: June, 310
radiographic appearance of, *1984*: June, 228–239

Melphalan, interstitial lung disease and, *1982*: Sept., 526, 527
Mendelson's syndrome, radiographic signs of, *1984*: June, 249
6-Mercaptopurine, interstitial lung disease and, *1982*: Sept., 523
Mesothelioma, pathology of, *1982*: May, 284–286
Metabolic abnormalities, with small cell carcinoma of lung, *1982*: May, 271
Metabolic acidosis, excessive, on exercise testing, *1984*: Mar., 196
Metabolic storage diseases, *1982*: Sept., 638, 639
Metastases, abdominal, from lung cancer, *1982*: May, 347–348
  bony, from lung cancer, *1982*: May, 347
  brain, from lung cancer, *1982*: May, 346–347, 418–420
  extrathoracic, imaging of, *1984*: June, 359–361
  generalized, from lung carcinoma, *1982*: May, 420
  pulmonary, CT evaluation of, *1984*: June, 269–270
Metastatic pulmonary nodule(s), diagnosis of, *1984*: June, 372
Methotrexate, interstitial lung disease and, *1982*: Sept., 528
Methylxanthines, complications of, for asthma, *1984*: Dec., 706
Mineralocorticoids, chemistry of, *1984*: Dec., 669
Minute ventilation, during exercise, *1984*: Mar., 36, 65
Mites, house-dust, as cause of asthma, *1984*: Dec., 602
Mitral stenosis, exercise testing in, *1984*: Mar., 176
  oxygen transport in, *1983*: May, 105
  pulmonary venous hypertension with, *1983*: May, 103
Mitral valve disease, exercise testing in, *1984*: Mar., 183–184
  pulmonary embolism after, right ventricular response to, *1984*: Sept., 430–431
Mixed connective tissue disease, collagen vascular disorders and, *1982*: Sept., 576
"Mixed emphysema," in epidemiologic studies, *1983*: Sept., 353
Monitoring, invasive hemodynamic, *1983*: May, 233–249
    complications of, *1983*: May, 240–244
    indications for, *1983*: May, 244–246
    technique of, *1983*: May, 233–235
Monocyte, as source of elastase, *1983*: Sept. 406
Motoneurons, discharge rates of, *1984*: Mar., 31
Mucolytic agents, for severe asthma, *1984*: Dec., 632
Mucus, excess production of, in asthmatics, *1984*: Dec., 570
    in emphysema, *1983*: Sept., 348
  impacted, as complication of severe asthma, *1984*: Dec., 702
Müller maneuver, *1983*: May, 106, 166, 169
Muscle(s), central nervous system activation of, *1984*: Mar., 27
  contractile failure of, *1984*: Mar., 24–25
  contractile speed of, *1984*: Mar., 30
  fuel utilization by, *1984*: Mar., 3
  injury to, endurance exercise and, *1984*: Mar., 70
  lipid oxidation by, *1984*: Mar., 8
  neural control of, *1984*: Mar., 27–29
  respiratory. See *Respiratory muscles.*
Muscle enzymes, endurance exercise and, *1984*: Mar., 69
Muscle fatigue, *1984*: Mar., **21–34**
  causes of, *1984*: Mar., 23–27
  central, *1984*: Mar., 25
  determining site of, *1984*: Mar., 24–25
  in endurance exercise, *1984*: Mar., 69
  role in respiratory failure, *1983*: Sept., 427
Muscle fiber(s), cardiac, *1983*: May, 105–106
  composition of, *1984*: Mar., 68
Muscle metabolism, maximal oxygen uptake and, *1984*: Mar., 54
Mustard gas, lung cancer and, *1982*: May, 225
Myeloperoxidase, role in emphysema, *1983*: Sept., 361
Myocardial disease, in sarcoidosis, *1984*: Mar., 151
  oxygen transport in, *1983*: May, 105
Myocardial failure, exercise testing for, *1984*: Mar., 175–179
Myocardial infarction, acute, radiographic findings in, *1984*: June, 257
  shock with, *1983*: May, 244
Myocardium, contractility of, effect of PEEP on, *1983*: May, 180
  oxygen consumption of, *1983*: May, 102

Needle aspiration biopsy, advantages of, *1984*: June, 371–372
  of bronchogenic carcinoma, *1984*: June, 350
  of hilar masses, *1984*: June, **365–377**
  of lung lesions, *1984*: June, 372–374
  of mediastinal masses, *1984*: June, **365–377**
    with CT, *1984*: June, 303
  of pulmonary masses, *1984*: June, **365–377**
Neocarzinostatin, interstitial lung disease and, *1982*: Sept., 525
Neonatal respiratory distress syndrome, alpha-1-antitrypsin and, *1983*: Sept., 368
Nephelemetry, for quantitating immunoglobulins, *1983*: Jan., 88–89
Neurofibromatosis, *1982*: Sept., 638
Neuromuscular fatigue, *1984*: Mar., 21–23
Neuromuscular transition, peripheral, failure of, *1984*: Mar., 26
Neutrophil(s), as source of elastase, *1983*: Sept., 405–406
  role in emphysema, *1983*: Sept., 360–361, 398
Newborn, persistent pulmonary hypertension of, *1983*: May, 212–215
Nickel, lung cancer and, *1982*: May, 225
Nifedipine, *1984*: Mar., 135
  in cor pulmonale, *1983*: May, 289
Nitroglycerine, for asthma, *1984*: Dec., 691
Nitroprusside, in acute hypoxic respiratory failure, *1983*: May, 255
Nitrosoureas, interstitial lung disease and, *1982*: Sept., 527, 528
Nitrous oxide, exposure to, in pathogenesis of emphysema, *1983*: Sept., 399
NMR. See *Nuclear magnetic resonance.*
Nodule(s), pulmonary. See *Pulmonary nodule(s).*
Noncaseating granulomas, sarcoid, *1982*: Sept., 538
    multiple, *1982*: Sept., 542
Nonchemotherapeutic drugs, interstitial lung disease and, *1982*: Sept., 529–532
Noncompliance, in asthmatic patient, *1984*: Dec., 711
Non-small cell lung carcinoma, therapy for, *1982*: May, **399–414**
    surgical, *1982*: May, 369–382
Norepinephrine, effects on ventricular function, *1983*: May, 262–263
Nuclear magnetic resonance studies, blood flow and, *1984*: June, 309
  contrast agents and, *1984*: June, 309
  for assessment of hilum and mediastinum, *1984*: June, 359
  general principles of, *1984*: June, 307–308
  image construction of, *1984*: June, 308
  imaging results of, *1984*: June, 309
  non–proton scanning and, *1984*: June, 309

of chest, *1984*: June, **307–312**
pathology and, *1984*: June, 310–311
pulse sequences of, *1984*: June, 308–309
Nutrition, immunocompetence and, *1982*: Jan., 102
in adult respiratory distress syndrome, *1982*: Jan., **101–108**
in renal failure, *1982*: Jan., 177

Oat cell subtype, of small cell lung carcinoma, pathology of, *1982*: May, 267–271
Obesity, exercise testing and, *1984*: Mar., 193
risk of pulmonary embolism from, *1984*: Sept., 395
Obstructive airway disease, chronic. See *Chronic obstructive pulmonary disease (COPD)*.
Occupational asthma, *1984*: Dec., 560, 595, **619–622**
immune factors in, *1983*: Jan., **43–53**
Occupational impairment, exercise criteria for, *1984*: Mar., 164
evaluation of, *1984*: Mar., 165–167
Occupational lung disease. See also specific diseases and causative agents.
exercise testing in, *1984*: Mar., **157–171**
immunologic techniques for diagnosis, *1983*: Jan., **85–95**
impairment vs. disability with, *1984*: Mar., 159
resting lung function vs. exercise testing in, *1984*: Mar., 160
Occupations, energy demands of, *1984*: Mar., 163
Oncofetal antigen, as marker of lung cancer, *1982*: May 315
Oral contraceptive drugs, risk of pulmonary embolism from, *1984*: Sept., 395, 512
Ouchterlony, double immunodiffusion technique of, *1983*: Jan., 89
Oximetry, ear, for monitoring oxygenation, *1982*: Jan., 187
Oxygen, effect on respiratory regulation, *1984*: Dec., 614
for severe asthma, *1984*: Dec., 628
Oxygen availability, lactate increase and, *1984*: Mar., 82
Oxygen consumption, base excess and, *1984*: Mar., 190
dead space ventilation and, *1984*: Mar., 191
heart rate and, *1984*: Mar., 190
in normal resting subject, *1983*: May, 102
maximal, as criterion for occupational impairment, *1984*: Mar., 165
of respiratory muscles, *1984*: Mar., 44
on exercise testing, *1984*: Mar., 190–192
ventilation and, *1984*: Mar., 191
Oxygen delivery, to periphery, *1983*: May, **139–148**
Oxygen-pulse, *1984*: Mar., 95
in COPD, *1984*: Mar., 125
Oxygen tension, mixed venous, *1983*: May, 240
Oxygen therapy, for complications of emphysema, *1983*: Sept., 472–476
for exercise performance in COPD, *1984*: Mar., 133
for pulmonary arterial hypertension, *1983*: May, **297–308**
in COPD, *1983*: May, 285
Oxygen toxicity, as cause of adult respiratory distress syndrome, *1982*: Jan., 198
pharmacologic modifications of, *1982*: Jan., 115
pulmonary, *1982*: Jan., **109–119**
pathologic changes, *1982*: Jan., 112–113
physiologic effects, *1982*: Jan., 113–115
Oxygen transport, *1984*: Mar., 53
in health and disease, *1983*: May, 104–105
in infants and children *1983*: May, 220
to peripheral tissues, determinants of, *1983*: May, 144
Oxygen-unloading capacity, *1983*: May, 221
Oxygen uptake, at anaerobic threshold, *1984*: Mar., 92
during exercise testing, *1984*: Mar., 91
maximum, *1983*: May, 104
in exercise performance, *1984*: Mar., **51–62**
peripheral, *1983*: May, **139–148**
alterations in, *1983*: May, 139–144
autoregulation of, *1983*: May, 145–146
Oxyhemoglobin dissociation curve, in hypoxia, *1983*: May, 140–141

Pacemaker(s), cardiac, radiographs to determine position of, *1984*: June, 263
Panacinar emphysema, in epidemiologic studies, *1983*: Sept. 353
pathologic classification of, *1983*: Sept., 330
Pancoast tumor, CT staging of, *1984*: June, 279
Pancreas, as source of elastase, *1983*: Sept., 406
Pancreatitis, as cause of adult respiratory distress syndrome, *1982*: Jan., 204–205
Panlobular emphysema, in epidemiologic studies, *1983*: Sept., 353
Papain, administration of, as cause of emphysema, *1983*: Sept., 389
in pathogenesis of emphysema, *1983*: Sept., 405
as cause of occupational asthma, *1983*: Jan., 47
Paracicatricial emphysema, in epidemiologic studies, *1983*: Sept., 353
pathologic classification of, *1983*: Sept., 330–331
Paradoxical pulse, *1983*: May, 108
Paralysis, risk of pulmonary embolism with, *1984*: Sept., 395
Paramorbidity, in staging, lung cancer, *1982*: May, 296
Paraseptal emphysema, pathologic classification of, *1983*: Sept., 330
Paraspinal line, displacement of, CT evaluation of, *1984*: June, 297
Parathyroid gland, CT evaluation of, *1984*: June, 300–301
Patent ductus arteriosus, circulatory pathology in, *1983*: May, 221–225
PEEP. See *Positive end-expiratory pressure*.
Percutaneous needle biopsy, for diagnosing lung cancer, *1982*: May, 325–327
Perfusion lung scintigraphy, in diagnosis of pulmonary embolism, *1984*: Sept., 457–458
Perfusion scans, for bullectomy, *1983*: Sept., 458–459
for pulmonary embolism, *1984*: June, 252
Pericardial effusion, pressure changes with, *1983*: May, 107
radiographic appearance of, *1984*: June, 239–246
Pericardial pressure, pleural pressure and, *1983*: May, 182
Pericardium, functional aspects of, *1983*: May, 107
Peripheral circulation, types of cells in, *1983*: May, 200
Peripheral shunt, functional, *1983*: May, 141
Persistent fetal circulation, *1983*: May, 212–215
PHA, in asbestosis, *1983*: Jan., 4
Philadelphia Pulmonary Neoplasm Research Project, *1982*: May, **243–256**
Physical activity. See *Exercise*.
Physical therapy, for patient with emphysema, *1983*: Sept., 477
Physical training, *1984*: Mar., 58. See also *Exercise*.
for endurance exercise, *1984*: Mar., 72–73
fuel-hormone metabolism after, *1984*: Mar., **3–11**
in COPD patient, *1984*: Mar., 137
Phytohemagglutinin, in asbestosis, *1983*: Jan., 4
Pigeon-breeder's disease, *1982*: Sept., 508–509
Pi system, for classifying variants of alpha-1-antitrypsin, *1983*: Sept., 363
"Pink puffer," *1983*: Sept., 333

Plasma lipoproteins, effects of exercise on, *1984*: Mar., 9
Platelet factor IV, role in stimulating neutrophil elastase, *1983*: Sept., 361
Plethysmography, impedance, in diagnosis of venous thromboembolic disease, *1984*: Sept., 386, 397, 441–444, 450–452
Pleura, CT evaluation of, *1984*: June, **276–279**
  thickening of, on ultrasound, *1984*: June, 286
Pleural effusion, in lung cancer, *1982*: May, **443–452**
  radiographic appearance of, *1984*: June, 252–253
Pleural fluid, ultrasound evaluation of, *1984*: June, 281–286
Pleural pressure, *1983*: May, 107
  effect on cardiac output, *1983*: May, 190
  increased, effects of, *1983*: May, 108
  measurement of, *1983*: May, 183
  pericardial pressure and, *1983*: May, 182
  pressure ventilation and, *1983*: May, 161–162
  variations in, *1983*: May, 108
Pleural space, normal, ultrasound appearance of, *1984*: June, 281
Pneumoconiosis. See also specific types and causative agents.
  classification of radiographs of, by International Labour Organization, *1984*: June, 332–333
    modified for application to other chronic diffuse infiltrative lung diseases, *1984*: June, 333–344
  coal workers', immune factors in, *1983*: Jan., 9–11
  exercise testing in, *1984*: Mar., 157–158, 161
Pneumonectomy, for lung carcinoma, *1982*: May, 375
  radiographic changes after, *1984*: June, 258
Pneumonia, as cause of acute respiratory failure, *1982*: Jan., 133
  as complication of adult respiratory distress syndrome, *1982*: Jan., 149–150
  aspiration, as cause of adult respiratory distress syndrome, *1982*: Jan., 197
  diffuse infectious, as cause of adult respiratory distress syndrome, *1982*: Jan., 198–199
  radiographic appearance of, *1984*: June, 250–252
Pneumonitis, aspiration, *1982*: Jan., 25–34
    radiographic appearance of, *1984*: June, 249–250
  familial lymphoid interstitial, *1982*: Sept., 638
  hypersensitivity, immune factors in, *1983*: Jan., **55–62**
    immunologic methods for diagnosis, *1983*: Jan., 75–78
    mistaken for asthma, *1984*: Dec., 697
  radiation, *1982*: Jan., 206
Pneumothorax, as complication of asthma, *1984*: Dec., 702
  pressure changes with, *1983*: May, 103
Point-counting, for determining extent of emphysema, *1983*: Sept., 353
Pollution, asthma and, *1984*: Dec., 560
Polycythemia, pulmonary artery pressure with, *1983*: May, 206
Polyethylene glycol assay, for diagnosis of occupational lung disease, *1983*: Jan., 91–92
Polymyositis, collagen vascular disorders and, *1982*: Sept., 574, 575
Pores of Kohn, distinguished from fenestrae, in emphysematous lungs, *1983*: Sept., 339
Positive airway pressure, effects of, *1982*: Jan., 161–163
Positive end-expiratory pressure (PEEP), cardiac changes with, *1982*: Jan., 64
  cardiac output and, *1982*: Jan., 163–165
  contraindications for, *1982*: Jan., 74–75
  effect on antidiuretic hormone release, *1983*: May, 180
  effect on arterial pressure, *1983*: May, 180
  effect on cardiac function, *1983*: May, 181
  effect on cardiac output, *1983*: May, 122–124
  effect on myocardial function, *1983*: May, 180
  effect on pleural pressure, *1983*: May, 161
  effect on pulmonary artery and wedge pressure measurements, *1983*: May, 238–240
  effect on radiographic appearance of lungs, *1984*: June, 262–263
  effect on venous return, *1983*: May, 122, 123, 179
  for adult respiratory distress syndrome, *1982*: Jan., 72–79; *1983*: May, 122–124, 256–260.
    radiologic considerations in, *1982*: Jan., **89–100**
  hemodynamic effects of, *1983*: May, 122–124
  indications for, *1982*: Jan., 74
  left ventricular compliance and, *1983*: May, 181
  physiologic changes with, *1982*: Jan., 61–64
  to increase arterial oxygen tension, *1982*: Jan., 61
  ventricular function during, *1983*: May, 181
  withdrawal of, *1982*: Jan., 77–78
Positive-pressure ventilation, in adult respiratory distress syndrome, *1982*: Jan., **69–88**
Postphlebitic syndrome, *1984*: Sept., **537–549**
  management of, *1984*: Sept., 545–547
  pathophysiology of, *1984*: Sept., 538–541
  prevalence of, *1984*: Sept., 537–538
  subfascial venous ligation for, *1984*: Sept., 547
  symptoms of, *1984*: Sept., 537
  venous reconstructive surgery for, *1984*: Sept., 547
Pregnancy, adult respiratory distress syndrome and, *1982*: Jan., 206
  complicating management of asthma, *1984*: Dec., 700
  corticosteroid therapy during, *1984*: Dec., 678–679
  risk of pulmonary embolism in, *1984*: Sept., 394
Pressure-flow curves, pulmonary, *1983*: May, 127–132
Procarbazine, interstitial lung disease and, *1982*: Sept., 528, 529
Prostacyclin, as vasodilator, *1982*: Jan., 13
Prostaglandins, for asthma, *1984*: Dec., 689–690
  in etiology of byssinosis, *1983*: Jan., 68
Protease-antiprotease balance, smoking and, *1983*: Sept., 361–363
Protease inhibitor function. See *Alpha-1-antitrypsin deficiency.*
Protein metabolism, exercise and, *1984*: Mar., 5
Psychosocial counselling, for patient with emphysema, *1983*: Sept., 478–479
Puerperium, risk of pulmonary embolism in, *1984*: Sept., 394
Pulmonary. See also *Lung(s).*
Pulmonary angiography, digital subtraction, *1984*: Sept., 472–476
  in diagnosis of pulmonary embolism, *1984*: Sept., **465–477**
    accuracy, *1984*: Sept., 469–470
    complications of, *1984*: Sept., 470–472
    contrast materials for, *1984*: Sept., 466
    timing of, *1984*: Sept., 466, 469
  indications for, *1984*: Sept., 472
  technique of, *1984*: Sept., 465–466
Pulmonary artery(ies), catheterization of, complications of, *1983*: May, 242
  radiographic appearance of, *1984*: June, 213, 217
  rupture of, *1983*: May, 243
Pulmonary artery circulation, at birth, *1983*: May, 201–202
  normal structure of, *1983*: May, 199–201
Pulmonary artery pressure, effects of respiration on, *1983*: May, 236
  in chronic obstructive pulmonary disease, *1983*: May, 269
  in polycythemia, *1983*: May, 206
  invasive monitoring of, *1983*: May, 233–238
    complications of, *1983*: May, 240–244

mean, cardiac index and, pulmonary embolism and, *1984*: Sept., 428
in hypobaric hypoxia, *1983*: May, 205
systemic arterial hypoxemia and, *1984*: Sept., 423
Pulmonary artery thrombosis, primary, vs. pulmonary embolism, *1984*: Sept., 512
Pulmonary artery wedge pressure, invasive monitoring of, *1983*: May, 235–238
Pulmonary barotrauma, PEEP for, *1982*: Jan., 74–75
Pulmonary blood flow, *1983*: May, 102–103
alterations in, *1983*: May, 152
IPPV and, *1983*: May, 176
Pulmonary blood volume, *1983*: May, 103
Pulmonary capillaries, blood volume of, as index of microcirculation after pulmonary embolism, *1984*: Sept., 435
direct visualization of, *1983*: May, 132
Pulmonary capillary wedge pressure, correlations with chest radiograph, *1984*: June, 255
recording *1983*: May, 109
Pulmonary circulation, *1983*: May, 102–103
control of, *1983*: May, 202
during exercise, *1983*: May, 103
hemodynamic aspects of, *1983*: May, 102
invasive monitoring of, *1983*: May, 233–238
normal structure of, *1983*: May, 199–201
Pulmonary dead space, Bohr, *1984*: Sept., 418
Pulmonary disease, acute, diagnostic imaging in, *1984*: June, **247–255**
chronic diffuse infiltrative, *1984*: June, **329–344**
chronic obstructive. See *Chronic obstructive pulmonary disease (COPD)*.
immune factors in, symposium on, *1983*: Jan., **1–95**
obstructive. See *Chronic obstructive pulmonary disease (COPD)* and specific disorders.
occupational. See *Occupational lung disease*.
Pulmonary edema, *1983*: May, 153
after pulmonary embolism, *1984*: Sept., 413
effect of lung inflation on, *1983*: May, 134
in adult respiratory distress syndrome, *1982*: Jan., 10; *1983*: May, 253–256
radiographic appearance of, *1984*: June, 257
Pulmonary embolectomy, *1984*: Sept., **495–505**
anesthetic management with, *1984*: Sept., 527
complications of, *1984*: Sept., 525, 527
in chronic unresolved pulmonary embolism, *1984*: Sept., **525–529**
results of, *1984*: Sept., 502–503
in chronic unresolved pulmonary embolism, *1984*: Sept., 529–532
transvenous catheter technique of, *1984*: Sept., 500
Pulmonary emboli, as complication of adult respiratory distress syndrome, *1982*: Jan., 143–144
Pulmonary embolism, acute, arterial hypocarbia with, *1984*: Sept., 417
management of, fibrinolytic agents in, *1984*: Sept., 409
mistaken for asthma, *1984*: Dec., 698
respiratory alkalosis with, *1984*: Sept., 417
age and sex distribution of patients with, *1984*: Sept., 392–393
arterial blood gas abnormalities after, *1984*: Sept., 416
cardiac index after, *1984*: Sept., 424–425, 427, 433–434
cardiac stroke work index after, *1984*: Sept., 432
chronic unresolved, blood gases in, *1984*: Sept., 528, 529
bronchial angiography in, *1984*: Sept., 522–523
clinical presentation of, *1984*: Sept., 514–516
diagnosis of, *1984*: Sept., 518–525
embolectomy in, *1984*: Sept., 525–529
factors predisposing to, *1984*: Sept., 511–512, 517
hemodynamic findings in, *1984*: Sept., 520–522, 528, 529
incidence of, *1984*: Sept., 510–511
laboratory and physical findings in, *1984*: Sept., 518
pathology of, *1984*: Sept., 512–514
perfusion scans and angiographic findings in, *1984*: Sept., 519
peripheral venography in, *1984*: Sept., 522, 524, 525
presenting symptoms of, *1984*: Sept., 517
pulmonary hypertension with, *1984*: Sept., 511
radionuclide angiocardiography in, *1984*: Sept., 525
roentgen findings in, *1984*: Sept., 518–519
surgical treatment of, *1984*: Sept., **507–536**
classification of, *1984*: Sept., 496–497
clinical correlates of, *1984*: Sept., 421
cor pulmonale after, *1984*: Sept., 408
CT findings in, *1984*: June, 270, 272
death from, factors leading to, *1984*: Sept., 405–406
diagnosis of, angiography in, *1984*: Sept., **465–477**
accuracy of, *1984*: Sept., 469–470
complications of, *1984*: Sept., 470–472
digital subtraction, *1984*: Sept., 386, 472–476
indications for, *1984*: Sept., 472
timing of, *1984*: Sept., 466, 469
chest radiography in, *1984*: Sept., 459
scintigraphy in, *1984*: Sept., **457–464**
interpretation of, *1984*: Sept., 459–463
ventilation-perfusion scanning and angiography in, *1984*: Sept., 386
early theories of, *1984*: Sept., 507–509
emergency diagnostic procedures for, indications for, *1984*: Sept., 407
epidemiology of, *1984*: Sept., 391–392
from venous thromboembolic disease, new challenges in, *1984*: Sept., **385–390**
risk factors for, *1984*: Sept., 392–396
gas exchange alterations after, *1984*: Sept., **411–419**
nonpulmonary factors in, *1984*: Sept., 415–416
hemodynamic effects of, *1983*: May, 120; *1984*: Sept., **421–437**
hyperventilation after, *1984*: Sept., 417
hypoxemia after, *1984*: Sept., 422–423
in patient with prior cardiopulmonary disease, hemodynamic changes after, *1984*: Sept., 426–429
incidence of, *1984*: Sept., 403
long-term prognosis of, *1984*: Sept., 407–408
natural history of, *1984*: Sept., **403–410**
pathophysiology of, *1984*: Sept., 403
prevalence of, *1984*: Sept., 391
annual, geographic, and ethnic variations in, *1984*: Sept., 392
prevention of, methods of, *1984*: Sept., 404
pulmonary artery mean pressure after, *1984*: Sept., 424–425, 427
pulmonary arterial occlusion after, restoring blood flow in, *1984*: Sept., 406
pulmonary edema after, *1984*: Sept., 413
pulmonary hypertension after, *1984*: Sept., 408, 422, 426
cor pulmonale and, *1984*: Sept., 408, 434
pulmonary infarction after, *1984*: Sept., 421
radiographic findings in, *1984*: June, 252
recurrent, prevention of, Kim-Ray filter in, *1984*: Sept., 404, 406
resolution of, *1984*: Sept., 435
mechanisms of, *1984*: Sept., 405
pulmonary capillary blood volume as index of, *1984*: Sept., 435
rate of, *1984*: Sept., 406–407

Pulmonary embolism (*Continued*)
right atrial mean pressure after, *1984*: Sept., 427, 428
right-to-left intrapulmonary shunting after, *1984*: Sept., 411–413
right ventricular filling pressure after, *1984*: Sept., 423
right ventricular function after, *1984*: Sept., 430–434
right ventricular response to, *1984*: Sept., 429–430
risk of, blood group and, *1984*: Sept., 395
cancer and, *1984*: Sept., 393–394, 514
Cushing's disease and, *1984*: Sept., 396
estrogen therapy and, *1984*: Sept., 395
heart disease and, *1984*: Sept., 393
hematologic disease and, *1984*: Sept., 396
immobility and, *1984*: Sept., 395
obesity and, *1984*: Sept., 395
oral contraceptives and, *1984*: Sept., 395, 512
pregnancy and, *1984*: Sept., 394
surgery and, *1984*: Sept., 394, 512
trauma and, *1984*: Sept., 394
severity of, predicting, *1984*: Sept., 403, 404
short-term prognosis of, *1984*: Sept., 406
total pulmonary vascular resistance after, *1984*: Sept., 429
treatment of, embolectomy in, *1984*: Sept., **495–505**. See also *Pulmonary embolectomy*.
Greenfield vena caval filter in, *1984*: Sept., 497–499
thrombolytic agents for, *1984*: Sept., **487–494**
ventilation-perfusion inequality after, *1984*: Sept., 414–415
ventricular function after, mortality and, *1984*: Sept., 434
vs. primary pulmonary artery thrombosis, *1984*: Sept., 512
Pulmonary fibrosis, in allergic bronchopulmonary aspergillosis, *1983*: Jan., 19
idiopathic. See *Idiopathic pulmonary fibrosis*.
lupus erythematosus and, *1982*: Sept., 568
Pulmonary fissure(s), radiographic appearance of, *1984*: June, 220–228
Pulmonary function, cardiac function and, *1983*: May, 101, 108–109, **149–159**
Pulmonary function tests, in detecting emphysema, *1983*: Sept., 345
prior to surgical therapy for lung cancer, *1982*: May, 370–372
Pulmonary gas exchange, alterations after pulmonary thromboembolism, *1984*: Sept., **411–419**
anaerobic metabolism and, *1984*: Mar., 84
asthma and, *1983*: May, 155
cystic fibrosis and, *1983*: May, 155, 157
effect of cardiovascular function on, *1983*: May, **149–159**
effect of exercise on, *1983*: May, 155–158
effect of PEEP on, *1983*: May, 122
heart failure and, *1983*: May, 153, 155
in COPD, *1984*: Mar., 125–128
in interstitial fibrosis, *1984*: Mar., 145–149
obstructive lung disease and, *1983*: May, 155
Pulmonary heart disease. See *Cor pulmonale*.
Pulmonary hemorrhage syndromes, *1982*: Sept., **593–605**
Goodpasture's syndrome, *1982*: Sept., 593–598
hemosiderosis, idiopathic pulmonary, *1982*: Sept., 600–602
vasculitis, pulmonary hemorrhage and, *1982*: Sept., 598–600
Pulmonary hypertension, after pulmonary embolism, *1984*: Sept., 408, 422, 426, 434, 511
anatomic and physiologic correlates of, *1983*: May, 199–217
drug-induced, *1983*: May, 208–211
gas exchange in, *1983*: May, 154
hemodynamic effects of, *1983*: May, 120
idiopathic, *1983*: May, 212
in chronic respiratory disease, *1983*: May, 298
in heart disease, *1983*: May, 269–273, 297–298. See also *Cor pulmonale*.
oxygen therapy for, *1983*: May, **297–308**
radiographic identification of, *1983*: May, 272, 273
structural changes with, *1983*: May, 202–215
vasodilator therapy for, *1983*: May, 309–319
ventilation-perfusion ratios in, *1983*: May, 155
with left-to-right shunts, *1983*: May, 225
Pulmonary infarction, after pulmonary embolism, *1984*: Sept., 421
prognostic significance of, *1984*: Sept., 408
as complication of adult respiratory distress syndrome, *1982*: Jan., 145
as complication of continous pulmonary artery pressure monitoring, *1982*: Jan., 166
Pulmonary infection. See *Infection, pulmonary*; see also specific type.
Pulmonary interdependence, *1983*: May, 134
Pulmonary lesions, needle aspiration biopsy of, *1984*: June, 366–368
Pulmonary mass(es), CT evaluation of, *1984*: June, 270–271
diagnosis of, *1984*: June, 372–374
needle aspiration biopsy of, *1984*: June, **365–377**
Pulmonary nodules, *1982*: May, **361–367**
multiple, *1982*: May, 365–366
solitary, *1982*: May, 361–365
CT evaluation of, *1984*: June, 267–269
diagnosis of, *1984*: June, 372
radiographic evaluation of, *1984*: June, **345–350**
staging of lung cancer and, *1984*: June, **345–363**
Pulmonary rehabilitation, of patient with emphysema, *1983*: Sept., 477–479
Pulmonary sarcoidosis, *1982*: Sept., **537–563**
cause and pathogenesis, *1982*: Sept., 543–545
chest roentgenogram, *1982*: Sept., 547–549
clinical, *1982*: Sept., 545–551
corticosteroid therapy for, *1982*: Sept., 555–558
definition, *1982*: Sept., 537–538
role of biopsy, *1982*: Sept., 551, 552
staging, *1982*: Sept., 552–555
bronchioalveolar lavage for, *1982*: Sept., 553–555
gallium scanning for, *1982*: Sept., 553
symptoms, *1982*: Sept., 546, 547
obstructed airways, *1982*: Sept., 549
Pulmonary scintigraphy, in diagnosis of pulmonary embolism, *1984*: Sept., **457–464**
interpretation of, *1984*: Sept., 459–463
perfusion, *1984*: Sept., 457–458
ventilation, *1984*: Sept., 458–459
Pulmonary thromboembolism, classification of, *1984*: Sept., 496–497. See also *Pulmonary embolism*.
gas exchange alterations after, *1984*: Sept., **411–419**
treatment of, vena caval interruption in, *1984*: Sept., 495–497
Pulmonary vascular disease, exercise testing in, *1984*: Mar., 103, 177
interventricular septum in, *1983*: May, 106
oxygen transport in, *1983*: May, 105
pulmonary gas exchange in *1983*: May, 154
systolic ventricular pressures in, *1983*: May, 106
Pulmonary vascular pathways, *1983*: May, 201
Pulmonary vascular resistance, *1983*: May, **127–137**
assessment of, *1983*: May, 131
changes with age, *1983*: May, 220
distribution of, *1983*: May, 131–136
effect of lung inflation on, *1983*: May, 133–136
in chronic obstructive pulmonary disease, *1983*: May, 269

in evaluating pulmonary vasculature, *1983*: May, 127
increased, right ventricular overload and, *1983*: May, 103, 120, 163
site of, assessing of, *1983*: May, 131
total, after pulmonary embolism, *1984*: Sept., 429
Pulmonary vasculature, compliance of, *1983*: May, 117
direct micropuncture of, *1983*: May, 131
evaluation of, pulmonary resistance in, *1983*: May, 127
growth of, *1983*: May, 220
Pulmonary vasculitis, *1982*: Sept., **607–618**
Pulmonary venous hypertension, exercise testing in, *1984*: Mar., 176
Pulmonary ventilation, during exercise, *1984*: Mar., 35–38
Pulse, paradoxical, *1983*: May, 108
Purpura, thrombotic thrombocytopenic, associated with adult respiratory distress syndrome, *1982*: Jan., 205

Radiation, exposure to, as cause of adult respiratory distress syndrome, *1982*: Jan., 206
ionizing, lung cancer and, *1982*: May, 225–226
Radioallergosorbent test. See *RAST*.
Radiograph(s), of chest, anatomic considerations for, *1984*: June, **213–246**
in detecting emphysema, *1983*: Sept., 345
in evaluating for bullectomy, *1983*: Sept., 456–458
symposium on, *1984*: June, **213–377**
of emphysema, *1983*: Sept., **433–442**
Radionuclide imaging, in cor pulmonale, *1983*: May, 275–278
Radionuclide scanning, for detecting metastases of lung cancer, *1982*: May, 345–348
Radionuclide scintigraphy, for staging of lung carcinoma, *1982*: May, 343–344
Radiotherapy, for complications of lung carcinoma, *1982*: May, **415–421**
for lung cancer, CT for planning of, *1984*: June, 275–276
for non–small cell lung carcinoma, *1982*: May, **399–414**
for small cell cancer of lung, *1982*: May, 392–394
RAST, for detecting fungal allergens, *1983*: Jan., 35
for detecting IgE antibody, *1983*: Jan., 87–88
for testing cross-reactivity of fungi, *1983*: Jan., 25
Reactive airway disorders, in children, *1984*: Dec., **635–643**
Renal failure, as complication of adult respiratory distress syndrome, *1982*: Jan., 148–149, 176–177
Resistance, of pulmonary circulation, *1983*: May, **127–137.** See also *Pulmonary vascular resistance*.
of venous return, calculation of, *1983*: May, 124–125
Respiration, assisted, hemodynamic effects of, *1983*: May, **161–187**
depth of, exercise and, *1984*: Mar., 35–38
frequency of, exercise and, *1984*: Mar., 35–38
pressure changes with, *1983*: May, 114–115
on pulmonary artery, pressure, *1983*: May, 236
spontaneous, hemodynamic aspects of, *1983*: May, 165–176
left ventricular function during, *1983*: May, 168–171
Respiratory alkalosis, with acute pulmonary embolism, *1984*: Sept., 417
Respiratory disease, chronic, pulmonary hypertension in, *1983*: May, 298
chronic obstructive. See *Chronic obstructive pulmonary disease*.
effect on left ventricular function, *1983*: May, 174
exercise testing in interpretation of, *1984*: Mar., . **189–206**
Respiratory distress syndrome, adult, abnormal gas exchange in, *1983*: May, 153–154
alpha-1-antitrypsin deficiency and, *1983*: Sept., 368
aspiration pneumonitis and, *1982*: Jan., **25–34**
causes of, *1982*: Jan., **195–212**
changes in lung parenchyma in, *1982*: Jan., **35–56**
complications of, *1982*: Jan., **143–155**
defined and historical perspective, *1982*: Jan., **3–7**
gas exchange in, *1982*: Jan., **57–67**
hemodynamic aspects of, *1983*: May, 120
hemodynamic management in, *1983*: May, **251–268**
hemodynamic monitoring in, *1982*: Jan., **157–169**; *1983*: May, 246
integrated approach to, *1982*: Jan., **171–179**
nutritional support in, *1982*: Jan., **101–108**
pathologic features of, *1982*: Jan., 5
pathophysiology of, *1982*: Jan., 71–72
PEEP in, *1983*: May, 122–124, 256–260
peripheral oxygen uptake in, *1983*: May, 145
PEEP for, radiologic considerations in, *1982*: Jan., **89–100**
positive pressure ventilation in, *1982*: Jan., **69–88**
pressure-volume relationships in, *1983*: May, 251–253.
radiographic findings in, *1984*: June, 254–255
shock and, glucocorticoids for, *1982*: Jan., **121–132**
symposium on, *1982*: Jan., **3–212**
Respiratory exchange ratio, in COPD, *1984*: Mar., 125
Respiratory failure, acute, diagnosis of, *1982*: Jan., 139
left ventricular function in, *1983*: May, 253–256
oxygen transport in, *1983*: May, 105
pneumonia and, *1982*: Jan., 133
right ventricular function in, *1983*: May, 260
radiographic findings in, *1984*: June, 247
Respiratory function, maximal, *1984*: Mar., 52
Respiratory gas exchange, in left-to-right shunts, *1983*: May, 224
in right-to-left shunts, *1983*: May, 228
Respiratory gas exchange ratio, *1983*: May, 105
Respiratory heat loss, in exercise-induced asthma, *1984*: Mar., 111–113
Respiratory impedance, measuring, *1984*: Mar., 102
Respiratory infection, asthma and, *1984*: Dec., 561, 595
chronic, complicating management of asthma, *1984*: Dec., 702
Respiratory mechanics, during CPR, *1983*: May, 192–193
Respiratory monitoring, in adult respiratory distress syndrome, *1982*: Jan., **181–194**
Respiratory muscle(s), clinical failure of, *1984*: Mar., **21–34**
coordination of activities of, *1983*: Sept., 428–429
fatigue of, *1984*: Mar., 43
response to exercise testing, *1984*: Mar., 103, 106
in asthma, *1984*: Dec., 613
in COPD, *1984*: Mar., 124–125
in emphysema, *1983*:Sept., 395, 421–432
increased contractility of, with theophylline, *1984*: Dec., 647
limiting oxygen consumption of, *1984*: Mar., 44
metabolism of, *1984*: Mar., 40–41
power of, measuring, *1984*: Mar., 102
pressure generation by, *1984*: Mar., 38–40
training of, *1983*: Sept., 429–430; *1984*: Mar., 45
Respiratory rate, tidal volume and, *1984*: Mar., 192, 195
Rheumatoid arthritis, alpha-1-antitrypsin deficiency and, *1983*: Sept., 368
collagen vascular disorders and, *1982*: Sept., 569–571
Rheumatoid factor, in coal workers' pneumoconiosis, *1983*: Jan., 10–11
Rib cage, contribution to tidal volume, *1984*: Mar., 38–39
Right atrial pressure, cardiac output and, *1983*: May, 115–116
Right-to-left shunts, *1983*: May, 227–230
Right ventricle, functional significance of, *1983*: May, 103
pump function of, *1983*: May, 102

Right ventricular afterload, *1983*: May, 166, 171
hemodynamic effects of volume expansion in, *1983*: May, 261–263
vasodilator therapy of, *1983*: May, 310
Right ventricular ejection fraction, *1983*: May, 279–280
in COPD, *1984*: Mar., 130
Right ventricular filling pressure, after pulmonary embolism, *1984*: Sept., 423
Right ventricular function, *1983*: May, 165–168, 309–310
after pulmonary embolism, *1984*: Sept., 430–434
evaluation of, *1983*: May, 274–279
in acute respiratory failure, *1983*: May, 260
in cor pulmonale, *1983*: May, 274–283
Right ventricular hypertrophy, with cor pulmonale, *1983*: May, 106
Right ventricular overload, effect on left ventricular function, *1984*: Sept., 430
hemodynamic effects of, *1983*: May, 120–122
in COPD, *1983*: May, 120
pulmonary vascular resistance in, *1983*: May, 103, 120, 163
venous return curves and, *1983*: May, 120–122
Right ventricular response to pulmonary embolism, *1984*: Sept., 429–430
Roentgenographic patterns, in interstitial disease, *1982*: Sept., 476
ground-glass, *1982*: Sept., 477
honeycomb, *1982*: Sept., 481, 494
nodular pattern, *1982*: Sept., 477
reticular pattern, *1982*: Sept., 477
reticulonodular, *1982*: Sept., 481

Salicylates, for asthma, complications of, *1984*: Dec., 707
Sarcoidosis, exercise testing in, *1984*: Mar., 149–152
immunologic methods for diagnosis, *1983*: Jan., 78
inherited interstitial lung disease and, *1982*: Sept., 639
maximal exercise tolerance in, *1984*: Mar., 151
myocardial disease with, *1984*: Mar., 151
pulmonary, *1982*: Sept., **537–563**
Scanning, I-125 fibrinogen, in diagnosis of venous thromboembolic disease, *1984*: Sept., 386, 397, 446–447, 450–452
ventilation-perfusion, in diagnosis of pulmonary embolism, *1984*: Sept., 386
Scintigraphy, in diagnosis of pulmonary embolism, *1984*: Sept., **457–464**. See also *Pulmonary scintigraphy*.
Sclerosis, progressive systemic, collagen vascular disorders and, *1982*: Sept., 571–574
tuberous, *1982*: Sept., 636–637
Sepsis, as cause of adult respiratory distress syndrome, *1982*: Jan., 201–202
S-F-C staging, for lung cancer, *1982*: May, 302
Shock, adult respiratory distress syndrome and, glucocorticoids for, *1982*: Jan., **121–132**
as cause of adult respiratory distress syndrome, *1982*: Jan., 200–201
experimental studies of, *1982*: Jan., 123–124
hemodynamic monitoring in, *1983*: May, 244–245
Shunt(s), arteriovenous, *1983*: May, 144
bidirectional, *1983*: May, 227
functional peripheral, *1983*: May, 141
left-to-right, *1983*: May, 221–227
right-to-left, *1983*: May, 227–230
Shunting, intrapulmonary, after pulmonary embolism, *1984*: Sept., 411–413
"Sick euthyroid" syndrome, as complication of adult respiratory distress syndrome, *1982*: Jan., 151
Silicosis, immune factors in, *1983*: Jan., 6–9
Sjögren's syndrome, collagen vascular disorders and, *1982*: Sept., 574
Skin testing, or fungal allergens, *1983*: Jan., 35
for occupational lung disease, *1983*: Jan., 85–87
Sleep disturbances, complicating management of asthma, *1984*: Dec., 702–704
Sleep hypoxemia, *1983*: May, 303–306
Slow-reacting substance of anaphylaxis, as leukotriene, *1982*: Jan., 17
Small cell lung cancer, *1982*: May, **389–398**
chemotherapy for, *1982*: May, 391–392
immunotherapy for, *1982*: May, 395
pathology of, *1982*: May, 262–274
radiation therapy for, *1982*: May, 392–394, 416
staging of, *1982*: May, 390–391
surgery for, *1982*: May, 394–395
Smelting, byproducts of, lung cancer and, *1982*: May, 226
Smoke inhalation, as cause of adult respiratory distress syndrome, *1982*: Jan., 197–198
Smoking, as cause of emphysema, *1983*: Sept., 348
as cause of lung cancer, *1982*: May, 222–223
as prognostic factor in lung cancer, *1982*: May, 237
as risk factor in emphysema, *1983*: Sept., 356–357
as risk factor in lung cancer, *1982*: May, 246
asthma and, *1984*: Dec., 561–562
bullous emphysema and, *1983*: Sept., 449
cessation of, in patient with emphysema, *1983*: Sept., 477
in prevention of emphysema, *1983*: Sept., 335
effect on alpha-1-protease inhibitor, *1983*: Sept., 407
emphysema and, *1983*: Sept., 333
in etiology of small cell lung carcinoma, *1982*: May, 262–264
in pathogenesis of emphysema, *1983*: Sept., 334, 400
passive, asthma and, *1984*: Dec., 594
protease-antiprotease balance and, *1983*: Sept., 361–363
Solitary pulmonary nodule. See *Pulmonary nodule, solitary*.
Spiramycin, as cause of occupational asthma, *1983*: Jan., 49
Spirometry, equipment for, *1982*: Jan., 182–183
in asthma, *1984*: Dec., 575–576
bullectomy, *1983*: Sept., 454–456
"Split pleura" sign, on CT, *1984*: June, 279
Sputum, of asthmatics, *1984*: Dec., 569
production of, in chronic bronchitis, *1983*: Sept., 338
Sputum cytology, for diagnosing lung cancer, *1982*: May, 232, 321–323
Squamous cell lung carcinoma, pathology of, *1982*: May, 257–262
SRS-A, *1982*: Jan., 17
Staging, of esophageal carcinoma, CT for, *1984*: June, 298–299
of lung cancer. See *Lung cancer, staging of*.
Starling resistor, model of, *1983*: May, 128, 129
Starling's law of the heart, *1983*: May, 119, 309
Streptokinase, in management of acute pulmonary embolism, *1984*: Sept., 409
in treatment of thromboembolic disease, *1984*: Sept., **457–494**
Stress, physiologic. See *Exercise*.
Stroke volume, in endurance exercise, *1984*: Mar., 68
Stroke work index, after pulmonary embolism, *1984*: Sept., 432
Subpleural emphysema, pathologic classification of, *1983*: Sept., 330
Surfactant, abnormalities in, with adult respiratory distress syndrome, *1982*: Jan., 6

Surgery, as risk factor for pulmonary embolism, *1984*: Sept., 394, 512
cardiac, radiographic changes after, *1984*: June, 260
complicating management of asthma, *1984*: Dec., 701
corticosteroid therapy before, *1984*: Dec., 679
extrathoracic, radiographic changes after, *1984*: June, 260
thoracic, radiographic changes after, *1984*: June, 258
venous thromboembolic disease after, prevention of, *1984*: Sept., 484
Swan-Ganz catheter, complications of adult respiratory distress syndrome, with use of, *1982*: Jan., 145
positioning of, radiography for, *1984*: June, 263
Sympathetic nervous system, in asthma, *1984*: Dec., 590–591
Systemic arterial circulation, intrathoracic and extrathoracic components of, *1983*: May, 103–104
Systemic arterial lines, complications of, *1983*: May, 241

Tachyphylaxis, with prolonged beta agonist therapy, *1984*: Dec., 664
Temperature. See *Body temperature*.
Terbutaline, in cor pulmonale, *1983*: May, 288
in COPD, *1984*: Mar., 135
Thallium-201 imaging, in cor pulmonale, *1983*: May, 282
Theophylline, cardiovascular effects of, *1984*: Dec., 647
for asthma, *1984*: Dec., **645–658**
for severe asthma, *1984*: Dec., 631
in cor pulmonale, *1983*: May, 287
in COPD, *1984*: Mar., 134
in emphysema, *1983*: Sept., 466–469
Thoracic compliance, *1983*: May, 109
Thoracic surgery, radiography after, *1984*: June, 258–260
Thoracoscopy, for diagnosing lung cancer, *1982*: May, 327
Thorax. See *Chest*.
Thrombectomy, for deep vein thrombosis, *1984*: Sept., 542
Thrombocytopenia, as complication of adult respiratory distress syndrome, *1982*: Jan., 151
Thromboembolic disease, venous. See *Venous thromboembolic disease*.
Thromboembolic hypertension, *1983*: May, 211–212
Thrombolytic therapy, administration of, *1984*: Sept., 491
contraindications to, *1984*: Sept., 489
for deep venous thrombosis, *1984*: Sept., 542–545
in treatment of pulmonary embolism and deep vein thrombosis, *1984*: Sept., **487–494**
monitoring, *1984*: Sept., 488
results of, *1984*: Sept., 490
selection of patients for, *1984*: Sept., 489
Thromboneurosis, *1984*: Sept., 451
Thymoma, CT detection of, *1984*: June, 299–300
Thyroid disease, complicating management of asthma, *1984*: Dec., 701
Thymus gland, CT evaluation of, *1984*: June, 299–300
Thyroid gland, CT evaluation of, *1984*: June, 293
Tidal volume, contribution of rib cage to, *1984*: Mar., 38–39
during exercise, *1984*: Mar., 36–37
respiratory rate and, *1984*: Mar., 192, 195
Tissue(s), oxygen requirements of, *1983*: May, 101, 104
peripheral, oxygen delivery to, *1983*: May, **139–148**
TNM system, for classification of non–small cell bronchogenic carcinoma, *1984*: June, 351
for lung cancer, *1982*: May, 297–298
Tobacco, as cause of lung cancer, *1982*: May, 222–223
Tomography, computed. See *Computed tomography*.
conventional, for assessment of hilum and mediastinum, *1984*: June, 357
mediastinal, in staging bronchogenic carcinoma, *1982*: May, 338–339
Toxic agents, interstitial disease and, *1982*: Sept., 459
response to, in experimental emphysema, *1983*: Sept., 397
Toxic shock syndrome, associated with adult respiratory distress syndrome, *1982*: Jan., 206
Tracheostomy, complications of, *1984*: June, 262
importance of, *1983*: Sept., 445–446
Training. See *Physical training*.
Transbronchial lung biopsy, *1982*: Sept., 494
Transfusions, blood, multiple, as cause of adult respiratory distress syndrome, *1982*: Jan., 203–204
Transmural aortic pressure, IPPV and, *1983*: May, 179
Transmural cardiac pressure, *1983*: May, 168
Transpulmonary pressure *1983*: May, 108
in COPD, *1984*: Mar., 121
Trauma, aortic, CT evaluation of, *1984*: June, 296
as cause of adult respiratory distress syndrome, *1982*: Jan., 199–200
as risk factor for pulmonary embolism, *1984*: Sept., 394
thoracic, as cause of adult respiratory distress syndrome, *1982*: Jan., 206
Trephine biopsy, or diagnosing lung cancer, *1982*: May, 326
Trimellitic anhydride, as cause of occupational asthma, *1983*: Jan., 50
Tuberculosis, miliary, associated with adult respiratory distress syndrome, *1982*: Jan., 205
Tuberous sclerosis, *1982*: Sept., 636–637
Tubes, for enteral feeding, types of, *1982*: Jan., 105–106
Tumorlets, in chronic pulmonary diseases, *1982*: May, 276

Ultrasonography, Doppler, in diagnosis of venous thromboembolic disease, *1984*: Sept., 444–446
diagnostic, of chest, *1984*: June, **281–290**
needle aspiration biopsy and, *1984*: June, 286
Urokinase, for acute pulmonary embolism, *1984*: Sept., 409
for deep venous thrombosis, *1984*: Sept., 542–545
for thromboembolic disease, *1984*: Sept., **487–494**

Vapors, chemical, as cause of occupational asthma, *1983*: Jan., 49–51
Varices, mediastinal, CT evaluation of, *1984*: June, 294
Vascular compliance, *1983*: May, 113–114
venous return curve and, *1983*: May, 116
Vascular function, cardiac function and, *1983*: May, 119–124
models of, *1983*: May, 113–118
multiple-circuit, *1983*: May, 117–118
single-circuit, *1983*: May, 113–117
single equivalent circuit, *1983*: May, 117, 118
vascular compliance and, *1983*: May, 113–114
venous return curve and, *1983*: May, 115–117
Vascular permeability, pulmonary, granulocytes and, *1982*: Jan., 19
Vasculitis, pulmonary, *1982*: Sept., **607–618**
angiitis, benign lymphocytic, *1982*: Sept., 612
Behçet's syndrome and, *1982*: Sept., 615
collagen vascular diseases, *1982*: Sept., 615
granulomatosis, allergic, *1982*: Sept., 612–614

Vasculitis, pulmonary (*Continued*)
Hughes-Stovin syndrome, *1982*: Sept., 616
hypersensitivity, *1982*: Sept., 614–615
lymphomatoid granulomatosis, *1982*: Sept., 611–612
midline granuloma, *1982*: Sept., 612–613
pulmonary hemorrhage and, *1982*: Sept., 598–600
Wegener's granulomatosis, *1982*: Sept., 608–611

Vasodilators, for pulmonary arterial hypertension, *1983*: May, 309–319
in cor pulmonale, *1983*: May, 287
Vasodilators, in COPD, *1984*: Mar., 135
Vein(s), great, collapsibility of, effect on cardiac output, *1983*: May, 113–115
Vena caval interruption, for treatment of pulmonary thromboembolism, *1984*: Sept., 495–497
Venography, contrast, in diagnosis of venous thromboembolic disease, *1984*: Sept., 386
in diagnosis of venous thrombosis, *1984*: Sept., 438–440
Venous ligation, subfascial, for postphlebitic syndrome, *1984*: Sept., 547
Venous reconstructive surgery, for postphlebitic syndrome, *1984*: Sept., 547
Venous return, resistance of, calculation of, *1983*: May, 124–125
Venous return curve, atrial pressure and, *1983*: May, 119, 162
effect of PEEP on, *1983*: May, 122, 123, 179
measurement of, *1983*: May, 118
right ventricular overload and, *1983*: May, 120–122
Venous thrombectomy, for deep vein thrombosis, *1984*: Sept., 542
Venous thromboembolic disease, after surgery, prevention of, *1984*: Sept., 484
diagnosis of, contrast venography in, *1984*: Sept., 386
cost-effectiveness of various methods of, *1984*: Sept., 448–449
Doppler ultrasonography in, *1984*: Sept., 444–446
evaluation of approach to, *1984*: Sept., 450–452
I-125 fibrinogen scanning in, *1984*: Sept., 386, 397, 446–447, 450–452
impedance plethysmography in, *1984*: Sept., 386, 397, 441–444, 450–452
practical noninvasive approach to, *1984*: Sept., 447–448
epidemiology of, *1984*: Sept., 385–386, 391–392
new challenges in, *1984*: Sept., **385–390**
prevention of, *1984*: Sept., 388, 396–398
dextran in, *1984*: Sept., 397, 483
oral anticoagulant therapy for, *1984*: Sept., 398
physiologic approach to, *1984*: Sept., 397
subcutaneous heparin in, *1984*: Sept., 387, 398
pulmonary hypertension with, pulmonary ventilation-perfusion distribution in, *1984*: Sept., 416
risk factors in, *1984*: Sept., 385, 392–396
treatment of, anticoagulant therapy in, dosage, route, and timing of, *1984*: Sept., 387–388
antithrombotic for, *1984*: Sept., 479–486
aspirin in, *1984*: Sept., 484
coumarin derivatives in, *1984*: Sept., 387, 482–483
heparin in, *1984*: Sept., 386, 479–481
new thrombolytic agents for, *1984*: Sept., 388, 488
streptokinase in, *1984*: Sept., 487–494
thrombolytic agents for, *1984*: Sept., **487–494**
urokinase in, *1984*: Sept., **487–494**

Venous thrombosis, acute recurrent, diagnosis of, *1984*: Sept., 449
diagnostic approach to, *1984*: Sept., 451–453
deep, heparin, for, *1984*: Sept., 542
postphlebitic syndrome and, *1984*: Sept., 538. See also *Postphlebitic syndrome*.
prophylaxis of, *1984*: Sept., 541–542
streptokinase for, *1984*: Sept., 542–545
thrombolytic therapy for, *1984*: Sept., 542–545
treatment of, *1984*: Sept., 542–545
urokinase for, *1984*: Sept., 542–545
venous thrombectomy for, *1984*: Sept., 542
diagnosis of, *1984*: Sept., **438–455**
noninvasive techniques for, *1984*: Sept., 440
venography in, *1984*: Sept., 438–440
differential diagnosis of, *1984*: Sept., 448
Ventilation, adequacy of, *1982*: Jan., 185
alveolar, in infants and children, *1983*: May, 219
control of, in asthma, *1984*: Dec., **607–617**
dead space, oxygen consumption and, *1984*: Mar., 191
during exercise, *1984*: Mar., 35–38
in chronic bronchitis, *1984*: Mar., 128
in emphysema, *1983*: Sept., 418–419; *1984*: Mar., 128
in experimental emphysema, *1983*: Sept., 396
mechanical, for patients with emphysema, *1983*: Sept., 476
for severe asthma, *1984*: Dec., 629–630
optimization of, *1982*: Jan., 188–190
oxygen consumption and, *1984*: Mar., 191
pattern on exercise testing, *1984*: Mar., 93
physiologic mechanisms influenced by, *1983*: May, 161–165
positive and negative pressure, effects on cardiac performance, *1983*: May, **161–187**
Ventilation-perfusion inequality, after pulmonary embolism, *1984*: Sept., 414–415
Ventilation-perfusion radionuclide scanning, for pulmonary embolism, *1984*: June, 252
in diagnosis of pulmonary embolism, *1984*: Sept., 386
Ventilation pulmonary scintigraphy, *1984*: Sept., 458–459
Ventilator therapy, effect upon radiographic appearance of lungs, *1984*: June, 262
Ventilators, characteristics of, *1982*: Jan., 70–71
Ventilatory muscles. See *Respiratory muscles*.
Ventilatory pump, efficiency of, *1984*: Mar., 42
energy consumption of, *1984*: Mar., 41–42
in exercise, *1984*: Mar., **35–49**
power output of, *1984*: Mar., 40–41
Ventricle(s), geometry of, *1983*: May, 165, 173
interdependence, *1983*: May, 105–108, 164–165, 171–174
Ventricular afterload, left, *1983*: May, 170–172
right, *1983*: May, 166, 171
Ventricular compliance, left, PEEP and, *1983*: May, 181
Ventricular function, after pulmonary embolism, mortality and, *1984*: Sept., 434. See also *Left ventricular function; Right ventricular function*.
during PEEP, *1983*: May, 181
Ventricular overload, right, hemodynamic effects of, *1983*: May, 120–122
Ventricular septal defects, circulatory pathology in, *1983*: May, 221–225
Vessels, NMR studies of, *1984*: June, 310
of chest, anomalies of, CT evaluation of, *1984*: June, 293
pulmonary, DSA of, *1984*: June, 314–315
Vinyl chloride, lung cancer and, *1982*: May, 226
Vital organs, blood flow to, CPR and, *1983*: May, 196

Vocational training, of patient with emphysema, *1983*: Sept., 479
Volume expansion, effects on ventricular function, *1983*: May, 262
Volume-pressure curve of lungs, in emphysema, *1983*: Sept., 346

Weather, asthma and, *1984*: Dec., 594
Wedge pressure. See *Pulmonary artery wedge pressure*.
Wegener's granulomatosis, *1982*: Sept., 608–611
Wheezing, during childhood, as sign of asthma, *1984*: Dec., 561
  recurrent, with acute respiratory infection, in children, *1984*: Dec., 637–638
WHO classification, of adenocarcinoma of lung, *1982*: May, 276
  of small cell lung carcinoma, *1982*: May, 267–274
Wood dust, as cause of occupational asthma, *1983*: Jan., 48
Work physiology, applied, *1984*: Mar., 163

Xanthine derivatives, effect on respiratory regulation, *1984*: Dec., 615

Zero time, importance in staging lung cancer, *1982*: May, 294